JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL ANNUAL REPORT The Juvenile Diabetes

JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL 2007 ANNUAL REPORT The Juvenile Diabetes Research Foundation International is the leading charitable funder and advocate for research on type 1 diabetes and its complications. Founded in 1970 by parents to find a cure for diabetes, JDRF has directed more than $1 billion in grants for diabetes research to the world’s leading laboratories, universities, and medical centers. Dedicated to research approaches that accelerate the discovery, development, and delivery of therapeutics, we aggressively pursue all promising avenues of science, make funding decisions based on vigrorous scientific and lay review, and annually direct more than 85 percent of expenditures to research and research-related education. To push the pace of type 1 diabetes science towards a cure, JDRF’s $1 billion, five-year Global Campaign, “From Research to Reality: The Campaign to Accelerate the Cure for Diabetes,” was launched in 2004. Through volunteers and staff at more than 100 locations worldwide, JDRF also provides social, emotional, and practical support to children and adults who are newly diagnosed with diabetes, and to their families. JDRF offers a diverse support network, including family-to-family programs provided by local chapters, extensive information on www.jdrf.org, a variety of online and print publications, and JDRF’s unique Online Diabetes Support Team, a person-toperson e-mail-based response program. Ta b le o f CO N T E N T S Letter from Leadership ................ 2 Research Review 2007..................4 JDRF Profiles ...............................13 Donor Support.............................28 Stem Cell Research Fund .......... 36 Cure Therapeutic Pathways ....... 37 Named Grants Program .............38 Financial Information .................43 JDRF Chapters & Affiliates ........50 Board Members & Senior Staff ..51 IFC2 JDRF exists for one reason: to find a cure for type 1 diabetes and its complications. To that end, over the course of fiscal year 2007, JDRF made significant strides in accelerating the pace of research leading to a cure. 1 Letter from Leadership F or JDRF, fiscal 2007 was another good year. We made significant strides in our principle objective— to show dramatic, transparent progress in addressing complications and, ultimately, finding a cure for type 1 diabetes. We funded more science than we ever have before, raised more money to support research than we ever have before, and conducted more human clinical trials—testing cure therapeutics for diabetes and its complications in people, not animals— than we ever have before. “ To continue to be able to accelerate the pace of science at ever increasing levels, our objective last year was to achieve at least 11 percent growth, which we exceeded. Of course, achievement in our field is not measured by projects or programs or dollars. All of us impacted by diabetes want results. Against our ultimate goal—a cure—we again fell short in the 2007 fiscal year. But we continued to speed the pace of science, piling discovery on top of discovery, breakthrough on top of breakthrough, and building the momentum of research leading to a cure. In that light, over the last year we made important progress. While maintaining our strong support of basic academic discovery science, we have over the last few years increased our emphasis on translating discoveries into actual therapies. Every day, we look for opportunities to support research that develops drug and therapeutic treatments, to fill gaps in the drug development pipeline. In the past 12 months, we’ve demonstrated progress ” in moving therapeutics along that pipeline to the marketplace most strikingly in two ways. First, we now have more than 30 human clinical trials underway, compared with just five at the start of 2000. JDRF launched eight human clinical trials in FY 2007 alone, and three trials are Phase III studies, the final stage before a company seeks FDA approval for a product or treatment. Second, our strategy of filling gaps in the drug development pipeline by helping small companies move through early clinical testing until bigger companies step in to fund the large trials needed for FDA approval of drugs and treatments for diabetes has begun to pay off. In the span of 10 days in September, two of the businesses we funded through our Industry Discovery and Development Partnership program signed agreements with major pharmaceutical companies to license and commercialize the diabetes treatments they have been developing—thanks to proof of concept trials funded by JDRF. The two agreements validate the concept behind JDRF’s strategies of filling research gaps and working with small industry participants. Biotech and pharmaceutical companies face many hurdles during the long and expensive path to drug approval. So our involvement at early stages can be critical in keeping programs like these alive and moving forward, to ultimately benefit people with type 1 diabetes and its complications. So with our goal in FY 2007 to show dramatic, transparent progress towards a cure, more than 30 human clinical trials, the development of two promising treatments being accelerated by large health care companies, and hundreds of scientific investigations spanning our five cure therapeutic focus areas illustrate just how successful the year has been. The scale and scope of JDRF-funded science continued to increase in FY 2007, as well. Last year, we committed more than $137 million for research to more than 700 projects, including more than $64 million in new science. All are far 2 and away records for JDRF. As a result, our total funding for diabetes research grants since our founding in 1970 now exceeds more than $1.16 billion. The revenue we generate makes all of this research funding possible. To continue to be able to accelerate the pace of science at ever increasing levels, our objective last year was to achieve at least 11 percent growth, which we exceeded. JDRF ended FY 2007 with just over $228 million in total public support and revenue, up more than $31 million over the previous year. Those strong results were based on the generosity of our donors and the hard work and commitment of our volunteers and staff around the world. And they reflect the excellence in execution of our core programs that has become a JDRF hallmark over the years. We’ve also increased our efficiency across the organization: in a year in which we set a record for revenue, we also managed to beat our budget for expenses by almost $2 million. As a result, in less than four years, our $1 billion, five-year campaign, “From Research to Reality: The Campaign to Accelerate the Cure for Diabetes,” is exceeding its interim targets; through the end of fiscal 2007, we had raised $767 million. Although our official timetable is to reach $1 billion by the end of the 2009 fiscal year, the campaign goal may well be reached a full year ahead of schedule. The dedication of our volunteers, donors, and staff enable JDRF to continue to target outsized goals, and then surpass them—in science, in fundraising, in excellence in execution, and in our focus on the donor. Year after year, our momentum continues to build. By maintaining a single-minded focus on our core goals and forging close, lasting relationships with donors, researchers, and volunteers around the world, we are accelerating the pace of science leading to a cure, and turning what we see as promising research into promises kept to ourselves and our loved ones that we will find a cure. Thank you, as always, for your continued and generous support. James C. Tyree Chairman, Board of Directors Arnold W. Donald President and Chief Executive Officer Mary Tyler Moore International Chairman Robert Wood Johnson IV Chairman of JDRF 3 JDRF has focused its portfolio of research over the past few years on five inter-related areas of science. [4] Research Review 2007 J DRF exists for one reason: to find a cure for type 1 diabetes and its complications. To that end, over the course of fiscal year 2007, JDRF made significant strides in accelerating the pace of research leading to a cure. This annual report will detail the overriding strategy for JDRF research in its pursuit of a cure, explain the scientific areas of focus where JDRF looks to advance research, and provide—in as simple-to-understand language as possible—some examples of the progress made in FY2007 towards those scientific goals. It is intended to provide the reader with an update of what happened during the past 12 months to speed the pace of research leading to a cure; but it also serves as a reference for donors, volunteers, and all members of the JDRF family to better understand the organization’s scientific direction and its cure therapeutic strategy, and as a roadmap of the points of progress that will lead, eventually, to a world without diabetes. each of the five cure therapeutic scientific areas. As we continue to focus on speeding the pace of science, we expect discoveries and breakthroughs to accrue and the momentum of research to continue to build. JDRF science focuses on five cure therapeutic areas: Autoimmunity, Regeneration, Replacement, Complications, and Metabolic Control. In addition, the organization funds “Accelerator” science that advances any or all of these therapeutic areas, such as technologies to image insulinproducing cells to better determine the efficacy of cure therapeutics aimed at restoring beta cell function, or developing biomarkers to judge the progress of therapeutics or treatments. A key aspect of JDRF research is our focus on filling gaps that—if left unfilled—would have a negative effect on our and others’ efforts to accelerate the pace of science leading to a cure. or pharmaceutical companies. Or they could be strategic, in the case of a laboratory that owns the rights to a promising diabetes-related compound, but fails to put significant resources behind the ongoing development of that product since it does not necessarily focus on diabetes as a key aspect of its strategy. JDRF can—and has—stepped in to fill gaps such as these and others, and as a result, has moved compounds, drugs, and treatments farther along the product development pipeline, in effect increasing the pace of science that can benefit people with type 1 diabetes and its complications. Measuring Research Progress There are several ways to measure the progress of JDRF’s research portfolio. One is in clinical outcomes for people with diabetes: Is research leading to JDRF Research JDRF Funding for Research: The largest charitable funder of type 1 diabetes research in the world, JDRF has focused its portfolio of research over the past few years on five interrelated areas of science. In FY2007, JDRF allocated more than $137 million in funding towards those five areas, including some 700 research programs, projects, and partnerships. Since its founding in 1970, the organization has supported more than $1.1 billion in science leading to a cure for diabetes and its complications. The mission of JDRF is to find a cure, fast; in the 2007 fiscal year, the objective of the organization’s research activities was to show dramatic, transparent progress in finding a cure for type 1 diabetes and treatments for its complications. As this report details, there is much progress to report within JDRF RESEARCH AT A GLANCE $137.9 Million n Autoimmunity n Regeneration n Replacement n Complications Focus Areas of Research n Metabolic Control These gaps could be financial, such as the funding gaps that small biotech companies regularly come up against when trying to conduct expensive proof-of-concept trials for drugs and compounds that show promise, but do not yet have the significant financial backing of larger drug development the development of treatments and therapeutics that make life better for people with diabetes, that reduce the risks of complications associated with the disease, and that enhance the chances for success of therapeutics focused on addressing the underlying causes of type 1 diabetes? Another is 5 RESEARCh REvIEw 2007 in advances that validate JDRF’s strategic approach, such as scientific programs that reached an advanced stage because JDRF stepped in and filled a gap in the product development pipeline. The last is purely scientific: Did JDRF-funded research move the ball forward in understanding and reversing the underlying autoimmune response that causes diabetes? Did science advance in regenerating or replacing insulin-producing cells? Were alternative sources of insulinproducing cells developed? Do we better understand how we might prevent the disease in at-risk patients, such as the siblings of those already with type 1 diabetes? In the pages that follow, we discuss detailed signs of research progress across JDRF’s five cure therapeutics in each of those areas: improving lives, making strategic advances, and making scientific advances. But there are also several overriding themes that evidence success, in stages, in our overall goal of accelerating the pace of science leading to a cure. For example, a clear indication that we are having an impact on medical research is the growth in the number of compounds and products in human trials. We are filling gaps in the drug and therapeutic development process and showing dramatic progress in moving therapeutics to tests in people, the crucial phase before drugs and treatments can be approved and made available to people with diabetes. In FY 2007, we launched eight new clinical trials, bringing our total of active trials to 33—compared with only five at the start of 2000. Another clear sign of progress is our increased ability to actively manage the science throughout our portfolio. We have created a series of discrete three-year goals, and established one-year milestones to track our progress against those goals. We now track the more than 700 grants and partnerships we make annually against 31 distinct targets. And over the course of the year, we made significant progress against those objectives in each of our five cure therapeutic goal areas: stopping the autoimmune attack that causes diabetes, regenerating or replacing insulin-producing cells, preventing or treating complications, and increasing the ability of people with diabetes to regain metabolic control. Another sign of our progress is the strong validation of our strategy to fill gaps in the diabetes treatment and therapeutic pipeline, working with small laboratories and companies to support proof-of-concept trials Autoimmunity at a Glance JDRF Funding for Autoimmunity Research: $38.5 million/28% of all JDRF research Human Clinical Trials: 12 currently underway Types of Research Involved: Immunology, Genetics, Beta Cell Biology I n type 1 diabetes, the immune system mistakenly attacks insulin-producing beta cells in the pancreas. Stopping that attack is essential to reversing diabetes, or halting its progression in people who are newly diagnosed. Without stopping the immune attack on beta cells, replacing cells by transplanting them or prodding them into regenerating would only work for a short time; the same autoimmune attack that caused diabetes in the first place would inevitably destroy the transplanted or regenerated insulin-producing cells. Key Research Goals • Accelerating the availability of immunotherapeutics, including anti-CD3 clinical trials. • Launching clinical trials to use drugs and therapeutics already approved for other diseases. • Research on specific molecules (antigens) targeted by the immune attack in diabetes. • Research that focuses on inducing immunoregulation. • Launching clinical trials of insulin-based therapeutics. • Research to better understand how diabetes begins and progresses. • Identifying biomarkers to gauge how well drugs and therapeutics are working. 6 RESEARCh REvIEw 2007 in the expectation that success will attract larger pharmaceutical companies to pick up and commercialize those products. A full description of that recent success is included in the section that discusses autoimmunity research. Finally, while our funded science is focused on cure therapeutic goal areas, we do not manage research to specific funding targets. JDRF’s strategy is to find and fund the gaps in science that we think will speed the pace of science and allow us to get to a cure faster. But it is worth noting that in fiscal year 2007, JDRF funded more science than it ever has before, approving more than $137 million in research. That included more than $67 million in new scientific projects. Both totals are far and away records for JDRF. Cure Therapeutics Advances There is much specific progress to report from FY2007 in each of our five cure therapeutics areas. Following is a detailed discussion of the science in each of those disciplines. Autoimmunity In the area of autoimmunity, JDRF is teaming with two of its industry partners to fund the first Phase III trials JDRF has ever sponsored. Phase III trials are the last stage before applying to the FDA for approval to bring a therapeutic to market. These trials are testing two different anti-CD3 antibodies in patients who have recently been diagnosed with type 1 diabetes. Our partners are TolerRx in Massachusetts and MacroGenics in Maryland; MacroGenics develops immune-based products to treat a range of diseases from cancer to diabetes. Anti-CD3 has been a success story for JDRF for the past two years, and illustrates the type of scientific momentum we hope to achieve across the various areas of our research platform. Science that JDRF and others have funded in this area has been steadily progressing. The research that this Phase III trial is building on showed that anti-CD3 antibodies could preserve the function of insulin-producing cells for up to 18 months among those newly diagnosed with type 1 diabetes. We believe we may be able to apply similar treatments, in combination with regeneration therapeutics, to reverse established type 1 diabetes. Two of JDRF’s Industry Discovery and Development Partnership (IDDP) partners have entered into global alliances with larger pharmaceutical companies to develop and commercialize anti-CD3 antibodies to treat early-stage Regeneration at a Glance JDRF Funding for Regeneration Research: $14.6 million/10% of all JDRF research Industry Partners: 4 current biotech partners Types of Research Involved: Beta Cell Biology E ven if you could stop the immune attack that kills insulin-producing cells and creates diabetes, you would need to replace the beta cells that were lost. Replacing cells by transplanting them from other sources is an option, but a difficult one. Discovering how the body can regenerate its own insulin-producing cells is a promising alternative. People with type 1 diabetes have too few insulinproducing beta cells to effectively convert sugar in their bloodstream into energy. However, research shows that even people who have had diabetes for decades have some insulin-producing cells remaining. Prodding those cells to regenerate more beta cells could reverse the symptoms of diabetes. Key Research Goals • Identifying key cellular targets for therapy. • Discovering biochemical pathways. • Discovering potential drug targets. • Discovering small molecules and biological factors. • Determining the viability of Gastrin combination therapeutics (regeneration agents). • Developing biomarkers to gauge the success of regeneration therapies. 7 Another clear sign of progress is our increased ability to actively manage the science throughout our portfolio. 8 RESEARCh REvIEw 2007 type 1 diabetes. The agreements demonstrate the success of JDRF’s strategy to fill gaps in the drug pipeline, by helping small companies move discovery research through early clinical testing until bigger companies step in to fund the large trials needed for FDA approval. MacroGenics entered into an alliance with Eli Lilly and Company to develop teplizumab, an anti-CD3 antibody that has been effective in clinical trials in slowing the progress of type 1 diabetes in newly diagnosed patients. A second JDRF partner, Tolerx, formed an alliance with GlaxoSmithKline to develop otelixizumab, another anti-CD3 antibody for type 1 diabetes. By funding early-stage testing and validation of anti-CD3 antibodies, including teplizumab at MacroGenics and otelixizumab at Tolerx, JDRF helped to “de-risk” this therapeutic, making it possible for smaller biotech companies to advance their antibodies through proof-of-concept clinical trials, attract additional funding, and eventually secure global licensing and marketing alliances with larger pharmaceutical companies. Biotech companies face many hurdles during the long and expensive path to drug approval, so JDRF’s involvement at early stages is often to address gaps (financial and otherwise) and keep programs like these alive and moving forward to benefit patients. The major focus for JDRF in IDDP partnerships is to accelerate the pace of applied research leading to a cure for type 1 diabetes and its complications. If these collaborative partnerships successfully commercialize cures and treatments, JDRF also shares in the financial results of that process, enabling the organization to recoup its initial support, and fund other research programs leading to a cure. Other important progress in combating the immune attack include: •Researchers at the University of Florida showed that in a small group of children with type 1 diabetes, transfusions of stored umbilical cord blood delayed progression of the disease, possibly by resetting the immune system and slowing the destruction of their insulinproducing cells. • An international research consortium, led by the Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory in Cambridge, U.K., has identified four new genetic regions that are involved in determining the risk for type 1 diabetes. This finding will help scientists better understand the disease pathway and someday provide a clearer picture of individual risk. Replacement at a Glance JDRF Funding for Replacement Research: $47.6 million/34% of all JDRF research Human Clinical Trials: 9 currently underway Types of Research Involved: Beta Cell Biology, Transplantation, Immunology, P eople with type 1 diabetes have too few insulinproducing beta cells to effectively convert sugar in their bloodstream into energy. Replacing, or transplanting, those cells with insulin-producing cells from other sources— such as human donors, animals, or stem cells—can often reverse the symptoms of diabetes. However, there is a shortage of cells available for transplant, and over time, the positive effects of replacing these cells eventually “wears off.” Key Research Goals • Proof-of-concept of beta cells derived from embryonic stem cells. • Find, isolate, and expand insulin-producing beta “precursor” cells. • Proof-of-concept of insulin-producing cells not derived from stem cells or beta cells. • Clinical trials of animal-derived insulin producing cells (xenotransplantation). • Proof-of-concept for “encapsulating” islets that can be transplanted. 9 RESEARCh REvIEw 2007 • A clinical trial in partnership with the NIH is testing another antibody, anti-CD20, which is already FDAapproved to treat a form of cancer and rheumatoid arthritis. Rituxan takes an entirely different approach to regulating the immune response: it targets and attacks immune B lymphocytes, which help activate the T cells that destroy insulin-producing cells in the pancreas. • JDRF is providing financial support to MediGene, a German biotechnology company, to advance monoclonal T cell receptor (mTCR) therapeutics that prevent the destruction of insulinproducing beta cells associated with the onset of type 1 diabetes. JDRF is collaborating with MediGene over two years to accelerate proof-of-concept studies into the clinic. • Using natural compounds derived from a shrub and the venom of a sea anemone, JDRF-funded researchers at the University of California-Irvine stopped the autoimmune attack causing diabetes in experiments with human cells and animals. In the research, the compounds blocked an ion channel in immune T cells that plays a critical role in allowing the cells to multiply and gear up for an immune attack. Their results suggest that the ion channel could be an important target for diabetes therapies. Regeneration The regeneration of insulin-producing cells has quickly moved from a concept into therapies that are being tested in human clinical trials. Overall, regenerative science is beginning to produce some very encouraging results. A highlight has been JDRF’s partnership with Transition Therapeutics, a small company that is testing drug combinations in people with diabetes to significantly increase their ability to produce insulin on their own. Transition Therapeutics is testing two different two-drug combinations, both of which are designed to increase the number of insulin-producing cells in the pancreas. One compound, E1-INT, produced promising early results, indicating that the compound did in fact expand the number of beta cells. As a result, JDRF funding is now helping to test a second-generation version of this drug, GLP1-INT, in human clinical trials. JDRF also established a partnership with DeveloGen, a biopharmaceutical company in Germany, to test drugs targeting a gene that is a key regulator of beta cell development. The goal is to activate the gene and spur beta cell regeneration. Complications at a Glance JDRF Funding for Complications Research: $29.6 million/22% of all JDRF research Human Clinical Trials: 5 currently underway Types of Research Involved: Trans-Complications, Retinopathy, Vascular, Nephropathy, Neuropathy P eople with diabetes are at risk of developing a range of serious complications—eye disease, nerve disease, kidney disease and heart disease—because of the toll diabetes takes on the body’s various systems. These complications can have a devastating impact on quality of life, and on life expectancy. Research in each of these specific areas, and into whether there are common pathways that can lead to any or all of those complications (trans-complications), is aimed at stopping, reversing, or preventing complications in people with diabetes. Even if you could cure diabetes—stop the immune attack that kills insulin-producing cells and replace them with functioning cells—people with type 1 diabetes would still be susceptible to complications after having lived with disease for a period of time. So it is important that in addition to research focused on a cure, research addresses complications that people with diabetes have already developed, or might develop in the future. Key Research Goals • Clinical trials with new and marketed drugs for trans-complications. • Validate new targets for trans-complications. • Validate new targets for eye, cardiovascular, nerve, and kidney disease. • Drug evaluation in macular edema and retinopathy. • Drug evaluation in nephropathy. • Develop surrogate endpoints for peripheral neuropathy. 10 RESEARCh REvIEw 2007 Our work with Transition Therapeutics and DeveloGen not only underscores the potential and progress of regeneration, but also serves as another example of how we are successfully joining with industry to speed existing drugs through the product pipeline. These projects are also part of JDRF’s Industry Discovery and Development Partnership program, which is focused on partnering with drug and biotechnology companies to accelerate the discovery, development and commercialization of therapies. We are currently working with 22 such companies, both in the U.S. and around the world. Last year, the Wall Street Journal noted how innovative and potentially successful partnering with industry could be. The paper published a positive and prominent story about JDRF’s partnerships and our success in leading the way in what they called “Venture Philanthropy.” Also last year, researchers at the University of Massachusetts identified a protein in beta cells that regulates the production of insulin. The finding points to the possibility that a drug or therapy that increases the activity of that protein could enable people with diabetes to boost their own insulin production and better manage type 1 diabetes. To ensure the identification of compounds that activate beta cell regeneration, JDRF also established in FY2007 multiple screening programs across the U.S ., including at Harvard, the Broad Institute, the Genomics Institute of the Novartis Research Foundation, and the Burnham Institute. Regenerative compounds uncovered for these programs will provide input into novel pathways and targets and possible therapeutic candidates. Replacement A key achievement over the past year in the area of islet replacement was the creation of putative beta cells from various cell sources. Another industry partner, the biotech company Novocell developed a way to convert human embryonic stem cells into insulin-producing cells. The cells created by Novocell do not secrete much insulin, and don’t do so in response to glucose, but this research represents a vital first step in coaxing stem cells to become cells that sense blood sugar and ultimately produce insulin in response. Other JDRF researchers, such as Anthony Atala of Wake Forest and those affiliated with the Pittsburgh biotechnology company Stemnion, explored whether stem cells collected from amniotic fluid or the placenta can give rise to insulin-secreting cells. Metabolic Control at a Glance JDRF Funding for Metabolic Control Research: $7.6 million/6% of all JDRF research Human Clinical Trials: 7 at hospitals, research centers and health centers Types of Research Involved: Medical Devices, Hypoglycemia R esearch shows that most people with type 1 diabetes could significantly improve their blood sugar control. Thus the development of devices that facilitate tighter control of blood sugar would have immediate health benefits for people with diabetes, particularly in avoiding dangerously low blood sugars, or hypoglycemia. Such devices would also reduce their risk of developing diabetic complications, and would aid in the effectiveness of other cure therapeutics, such as beta cell replacement or regeneration. The complexity of diabetes research, and the long lead times for the introduction of drugs and therapies, means that the development of cure therapeutics is a time-consuming process. To deliver near-term improvements in the quality of life for people living with type 1 diabetes, and to increase their chances of preventing complications, JDRF research also focuses on metabolic control and hypoglycemia. Key Research Goals • Continuation of the JDRF Continuous Glucose Sensor trial. • Home trials of automated insulin pumps—an artificial pancreas prototype. • Human drug trials to treat metabolic stress. • Human drug trials to prevent hypoglycemia. 11 RESEARCh REvIEw 2007 Other advances included: • Programs at the University of Minnesota and Emory University investigated the use of transplanted pig islets to replace lost insulinproducing cells. • JDRF-funded researchers have developed a way to protect the islets after a transplant so they survive longer and perform better, reducing the amount needed to restore blood sugar control. The researchers used gene therapy to trigger the release of glucacon-like peptide 1, a hormone in islets that strengthens beta cells and stimulates them to secrete insulin. Complications In addressing the complications of diabetes, we have seen significant progress in filling research gaps and moving treatments farther along the product development pipeline. Several drugs aimed at helping people with diabetic eye disease are currently in human clinical trials. JDRF is collaborating with Genentech to test a drug called Lucentis in a Phase II trial for diabetic macular edema. We are also planning a Phase II trial testing this drug against diabetic retinopathy. Lucentis has already been approved by the FDA for age-related macular edema, so the journey to the market for diabetic complications could be accelerated if Lucentis proves valuable in stopping or reversing those conditions. JDRF is also testing another drug already marketed, Avastin, as a retinopathy treatment. Avastin has been approved by the FDA for use in cancer therapy. In addition, we saw progress in fiscal year 2007 on a number of scientific fronts: • Two pharmaceutical companies, Pfizer, Inc., and TransTech Pharma, reached a licensing agreement last year to develop and commercialize drugs targeting a molecule called RAGE to combat diabetic retinopathy, nephropathy, neuropathy, and heart disease. The RAGE drugs resulted from 16 years of research initiated with JDRF funding at Columbia University School of Medicine. • JDRF began investing up to $8.9 million over five years to expand diabetes-related eye disease research at the Penn State Milton S. Hershey Medical Center and Penn State College of Medicine. The Penn State research will focus on developing and delivering new treatments and therapies for diabetic retinopathy. • JDRF last year formed a partnership with Sangamo BioSciences, Inc., to support Sangamo’s Phase II human clinical studies of SB-509, a therapy using a zinc-finger protein for the treatment of diabetic neuropathy. Metabolic Control JDRF’s groundbreaking project to accelerate the development of an artificial pancreas, the JDRF Artificial Pancreas Project, addresses the goal of achieving precise metabolic control. Enrollment in the Real-Time Continuous Glucose Monitor (CGM) Trial continued through FY2007, and a number of participants have already been active in this first clinical trial to measure how well blood sugar can be controlled using continuous glucose meters, compared with the more conventional fingerstick method. The project is a massive one, involving nine sites across the U.S. The demand among patients to participate was very high, and within a few months the waiting list exceeded over 1,000 people. JDRF has completed the enrollment of more than 400 patients in the CGM trial, which looks to provide independent statistics on the effectiveness of CGMs, with an aim of speeding reimbursement and clinician adoption of the technologies. Thanks to JDRF’s advocacy, Medicare made a preliminary decision to grant codes for CGMs, to enable public and private health insurance plans to process payments for the devices. Often, people seeking coverage of CGMs through their insurance plans lack such codes, and that has impeded access to these technologies. Since private insurance plans follow the same codes as Medicare, this milestone should have a huge impact in enabling patients to get CGM coverage. JDRF’s evidence-based clinical trials will be another key for insurance coverage. On this track, JDRF partnered with the FDA to begin to clarify the regulatory pathway to an artificial pancreas, which the FDA has made a “critical path” goal. In addition to helping expand the use of CGMs, JDRF is helping lay the groundwork for a safe and effective artificial pancreas. A project at Boston University is investigating use of the hormone glucacon in tandem with insulin in a closed-loop setting. Because glucagon raises glucose levels quickly, it could make an artificial pancreas much safer by reducing the risk of hypoglycemia. Researchers have also successfully closed the loop for the first time—teaming a CGM with an insulin pump system— in an early feasibility trial at Yale University involving children. And JDRF has funded seven research sites around the world that are focused on perfecting closed-loop systems, including creating algorithms to safely and effectively direct insulin delivery based on CGM readings; and taking into account the whole range of variables that people with diabetes currently have to calculate on their own, from current blood sugar, to the direction it’s trending, to what and how recently patients have eaten, to the impact of exercise and an individual’s sensitivity to insulin. 12 JDRF Profiles JDRF can exist for this reason: our volunteers and donors. The tireless efforts of thousands of people, who every day evidence commitment and a passion to find a cure for diabetes, enables JDRF to fund research leading to a cure. 13 Fulfilling a Vision Becky Hare & Nancy Shugart B “ ecky Hare lost her oldest son Kevin to type 1 diabetes 15 years ago. Diagnosed at age 3, he died from complications two weeks after his eighteenth birthday. Nancy Shugart has been blind since the age of eight, but it was type 1 diabetes—diagnosed when she was an adult of 35—that forced her into premature retirement from a successful 21-year career as a public school teacher. Together, with a bold “nothing can keep us down” spirit, Becky and Nancy found a way to turn their personal losses into significant gains in the fight against diabetes. I always surprise people when I tell them that if I could be cured of either my blindness or my diabetes, I’d chose diabetes. It’s the diabetes that threatens my life and the quality of my life. I’ve give anything to get diabetes cured. The two had first met years before at the JDRF Walk, and both had gone on to serve on the Board of Directors of the JDRF Austin (TX) Chapter, but it wasn’t until 2002 that their dynamic collaboration was born. “I had seen our schools raise a ton of money for other charities, and I thought, why couldn’t we start a really successful kids walk program benefitting JDRF?” recalls Nancy; and when she shared her vision with her friend Becky, “a light went on.” Through countless brainstorming sessions they developed a presentation that would not only educate elementary school students about diabetes but motivate them to participate in fundraising for a cure. “We wanted to do the presentation ourselves, and we agreed it had to be fast-paced and fun for the kids,” Nancy explains, and so they included a puppet, some magic ” tricks, video, and even a guest appearance by Nancy’s beloved guide dog, Luke. They also sought to create excitement through a variety of incentives, including prizes for the kids, and a 10 percent giveback to the school to be used for critically needed equipment or programs. Once they had a plan in mind, they met with the Executive Director of the Austin Chapter. With a quick “lets go for it” response, the powerhouse duo officially became Co-Chairs of the JDRF Kids Walk in Cure Diabetes in Austin. The inaugural year attracted two schools and raised an impressive $10,000. The following year, 14 schools brought in $42,000. And the third year, boosted by great word-of-mouth and canny salesmanship, an unprecedented 36 schools signed on and raised a remarkable $243,000—an increase of 2,400 percent. Over that time, Nancy and Becky put in hundreds of hours of their time and one hundred percent of their hearts and souls. Becky, who has two adult sons and three step children, says the Kids Walk program has been the fulfillment of her pledge to continue the fight for a cure after Kevin’s death. Both women say that the most rewarding aspect of the experience has been connecting with children who have diabetes themselves or have a close friend or family member with diabetes. Now their vision includes finding ways to replicate their success nationwide. The two have presented their program at JDRF conferences and were featured in a training video. “We’re getting closer,” Becky says about research advancements. “My family keeps getting bigger, I just don’t want diabetes to happen to anyone else.” For Nancy—the Austin Chapter’s 2005 Volunteer of the Year—finding the cure is a life’s calling. “I always surprise people when I tell them that if I could be cured of either my blindness or my diabetes, I’d chose diabetes. It’s the diabetes that threatens my life and the quality of my life. I’ve give anything to get diabetes cured.” 15 Raising the Bar Bob, Renee, & Michael Samuels B “ ob and Renee Samuels’ son, Michael, was diagnosed with type 1 diabetes in 1988 when he was l6. “Because he was a teenager, Michael immediately took charge of his own care,” says Renee. To prove it, he insisted on competing in a wrestling tournament less than two weeks after his hospital discharge, “while we were in total shock—hung up on food, shots, insulin reactions...all the usual parental worries,” says Bob. “But from the beginning, we also began thinking about what were the most important things we could do for our son that would make a difference.” What they could take charge of, the Samuels decided, was making sure Michael had the finest medical care, the most informed advice, and best hope for the future through research. Renee and I want a cure, but we also want a better quality of life for our son as long as he must live with diabetes. JDRF was there from the start. Bob and Renee describe a defining moment just after Michael’s hospital discharge, when a friend (and JDRF volunteer leader), Arnold Chase—himself diagnosed at 16—insisted on talking privately to Michael. “He told me I’d eat ice cream again,” Michael recalls, “and he advised me to keep myself in as good shape as possible for the day when research could make things better.” For Renee, JDRF became “the family that understands.” The Samuels family—which then included three other children and ” today encompasses eight grandchildren—soon assumed a host of volunteer roles at the North Central CT/Western MA Chapter in Hartford. Bob, a real estate developer and former supermarket executive, serves on the chapter board and over the years has played a pivotal role in developing the chapter’s Walk and other core programs, boosting fundraising goals, and enlisting corporate partners like Marshalls, Finast, and Stop & Shop as Walk sponsors. As the 1996 honoree at his chapter’s gala, Bob helped set a new record. “Before we had honorees at our galas, we would raise perhaps $50,000 a year,” he recalls. “That night, Renee and I announced our pledge to match the net revenue of the event, bringing the total to $800,000, a new record, and that trend has continued ever since.” In 2007, the chapter hit another milestone of over $1.3 million. Bob has also shared his business expertise on a national level by serving terms on JDRF’s International Board of Directors and Board of Chancellors, most recently focusing on growing the Major Gifts program. And over the last 18 years, the Samuels have committed more than $2 million, including a major gift this past winter to the Research to Reality Global Campaign. The Samuels have been heartened and reinvigorated by JDRF’s recent emphasis on cure therapeutics. “Renee and I want a cure, but we also want a better quality of life for our son as long as he must live with diabetes,” Bob says. Looking back on his nearly 20 years of life with diabetes—and speaking as a parent of two young children of his own—Michael now believes it was easier being the teenager dealing with a diagnosis than being the parent. “I can’t imagine having to worry about one of my kids going through what I had to,” he says, and he expresses a renewed sense of gratitude towards his own parents. “I know many kids whose parents just went with the flow, but my parents took a stance and joined the fight to help me and millions of others.” 16 A Special Connection Dan & Pat Wagner I t’s often said that it’s not just a child who gets diabetes, but the whole family; and grandparents can be an integral part of the mix. Dr. Dan Wagner and his wife, Pat, describe the “bolt out of the blue” phone call late on a fateful Friday afternoon, when their daughter, Suzy, informed them that her third child, 3-year-old Molly, was exhibiting the symptoms of type 1 diabetes. “ we’re confident that with the prayer and support of grandparents like us, this dreadful disease will be conquered. In an instant, the elder Wagners became active participants in an unfolding family drama. Dan rushed over to stay with Suzy’s other two preschoolers, and within hours Molly was admitted to the hospital. Operating with a weekend pared-down staff, the hospital couldn’t assign a doctor to Molly. “That first weekend was devastating, and we had many more questions than answers,” says Dan. Fortunately, late Saturday afternoon, a JDRF volunteer parent appeared at Suzy’s home with a “Bag of Hope” —a care package of materials and information for families with a new type 1 diagnosis, “and from that day forward,” Dan says, “all the staff and families of JDRF took our family under their wing.” Aided by firm support, the couple quickly learned that they had to deal with the same emotions and adjust- ” ments as the rest of the family and then determine how they could help. In their case, that meant stepping in to give Suzy and her husband Mark some needed time off. As the parents of five children and ten grandchildren—nine of whom live in town—they were able to seamlessly assume caregiving responsibilities for Molly. And as activist members of JDRF, they’ve done everything they can to work for a cure. Through the Omaha Council Bluffs Chapter, they’ve devoted their time, talent, and treasure by becoming Walk recruiters, Gala planners, and generous donors to helpfund JDRF’s research portfolio. Their most recent contribution of $100,000 was a lead gift to kick off the major giving campaign effort in their chapter. ”We’ve never shied away from giving our time and money where it was needed, and we’ve always supported children and their needs,” says Pat, “so when diabetes came into our lives, we made JDRF our number one charity.” For Dan, who had retired at age 62 a physician because of a heart condition, tracking type 1 diabetes research has become a focal point of his life. The Omaha Chapter arranged for Dan and Pat to meet and share views with members of the JDRF Lay Review Committee and JDRF’s Artificial Pancreas Project, and the couple toured the labs of a JDRF-funded researcher at the University of Nebraska. “I’m well aware of the shortcomings of many funded research projects,” Dan says. “But with JDRF, and its push to collaborate with drug companies and other agencies, I have no doubt that they’ve created the perfect blueprint for a cure.” The Wagners say that Molly is a free spirit who’s been able to roll with the punches so far, “so we found it heartrending when she threw away her ID bracelet when going through airport security recently, crying ‘I don’t want to have diabetes anymore!’ We’re confident that with the prayer and support of grandparents like us, this dreadful disease will be conquered.” 19 A Family’s Bond Kris, Maurine, Kathi & Kurt Bagwell F “ or all its cruelties and difficult challenges, a type 1 diabetes diagnosis can also bring a tight-knit family even closer together. Nearly 22 years ago, Kris Bagwell, then 24, was discharged from the hospital on a Thursday—a week after his diagnosis had come as a shock to him and his loved ones. Yet he made it with flying colors to his wedding that Sunday. “Before we’d hardly absorbed what had happened, Kris was dealing with it in his characteristically smart and disciplined way,” says his sister, Kathi. “Our parents, our brother, Kurt, and I rallied around him right away.” Kris has educated us so throughly on JDRF’s efficiency and the incredible progress it’s making on treating and curing the disease. ” Multi-talented and multitasking, Kris lives with his wife, Lisa, and sons Brendan, ll, and Trevor, 4, in Atlanta. With a varied career in media in New York and Atlanta that includes 15 years with MTV and Nickelodeon, he now heads a media production and consulting company and partners in another that produces video programming aimed at parents. He also has found time to be a dynamic JDRF volunteer leader who intensely follows and evaluates diabetes research and has been persuasive enough so that every member of his family shares his passion. Recently, Kris has focused that passion on JDRF’s therapeutic pathway of Metabolic Control. For nearly two decades, his diabetes had been well controlled, but then hypoglycemic unawareness developed, leading to several episodes of falling unconscious. A pivotal moment occurred a year ago. Having just dropped Brendan off for his guitar lesson, Kris remembers getting a low feeling, then awakening in an ambulance—the police had smashed his car window after he had lain unconscious for more than two hours. Aware of how close he had come to seriously endangering not only himself but his son as well, Kris acquired a continuous glucose sensor almost immediately and hasn’t had a similar episode since. He’s excited about the potential of a closed-loop artificial pancreas “to keep me and other type 1s healthy until we get to a biological, integrated cure,” he says. Kris first served on the Atlanta Chapter’s Board of Directors in the mid-1980s and became its president last July. One of his top priorities is to bring more adults with type 1 into the JDRF family. Another has been major gifts, an area where he and his parents, Maurine and Ken, had already led by example. So last year, when he asked his mother, Kathi, and Kurt (the family had sadly lost Ken after an accident the year before) to join him in a $260,000 family gift, they were already aboard. “It was easy for the family to come together, yes, because we want a cure,” says Kurt, “but also because Kris has educated us so throughly on JDRF’s efficiency and the incredible progress it’s making on treating and curing the disease.” He says the family has always been proud of Kris and his dedication. “When diabetes struck, he could have said ‘woe is me’, but instead he stepped up and said ‘let’s do something about it.’ Our gift was a no-brainer for all of us.” Echoing her children’s sentiments, Maurine says she is extremely proud of Kris for the way he has managed his diabetes “and especially for his fervor on behalf of JDRF and its cause. I pray every night for Kris and everyone with this disease.” 20 21 The Gift of Caring Patricia Wheeler A “ fter more than 50 years, Patricia Wheeler still vividly remembers the exact moment when type 1 diabetes struck her firstborn son, Andrew, at the age of six, and again when her other son, Tobin, was diagnosed three years later, when he was four. “I recognized the symptoms from lessons I had learned in school,” she recalls, “and I diagnosed it myself practically immediately. Unfortunately, I was right on both occasions.” I’d like to see somebody find a cure, and I’m glad I can help. Diabetes treatment was still in its infancy then. Patients and their families had to rely on unreliable urine tests, and there was no home glucose monitoring. As a result, Patricia and her husband, William, had no idea what their sons’ blood glucose levels were at any given time. They were lucky that both were able to maintain their blood sugar levels fairly well. “We didn’t have today’s technology,” Patricia says, “but we dealt with all the same issues then as now: giving shots, worrying all night, sleepovers, school. Diabetes was always there.” Patricia also remembers their early efforts to join the fight for a cure. “When Andy was first diagnosed, we assumed there were a lot of scientists working hard to find a cure, and I thought, this is going to be taken care of,“ she recalls. “We quickly found out that there wasn’t much research about type 1 at all.” Years later, Patricia read about a new parent-founded organization on the East Coast, then called the Juvenile Diabetes Foundation, and the ” Wheelers became loyal contributors to the national organization while continuing to raise awareness locally and lay the groundwork for a future chapter in Portland. Fortunately, Andrew and Tobin grew to adulthood without experiencing any major diabetes-related problems, and they eventually moved away and started families of their own. But in 1985, at a time when Patricia and William might have begun slowing down and letting others lead the charge to a cure, diabetes struck Andrew’s son Mathew, at age 2. Patricia remembers the same feeling of panic when she heard the news, and the couple knew they had to keep doing everything they could. After Williams death 11 years ago, Patricia extended her support by establishing a charitable remainder trust, providing her children with an income strea through her lifetime, with JDRF using the remaining assets to fund research. More than a loyal supporter, Patricia is also a good, caring friend who looks out for her chapter. On any given day, she might be passing on articles she’s found about diabetes research, stuffing envelopes, or donating a much-needed bookcase for the chapter’s conference room. Her most indelible contribution may well be the beautiful baby sweaters she knits and then embroiders with the child’s name. For the last ten years, the sweaters have been sold to benefit JDRF. “People seem to love them, and I had a friend recently tell me that it’s the best baby gift on the planet,” she says, adding with typical modesty, “but don’t you dare print that!” She now shares her home with a cockapoo named Casey. But with her two daughters still living in Portland, seven grandchildren, four great grandchildren, and work to be done to find the cure, her life is full. Asked about her philosophy of giving, she states with characteristic simplicity, “I’d like to see somebody find a cure, and I’m glad I can help.” 23 Leading a Crusade Pam Edmonds & Chair Family S erving as Chair Family of JDRF’s Children’s Congress stands out as one of the most rewarding and powerful experiences of her family’s life, says the 2007 “ChairMom” Pam Edmonds. “When an incredible group, a critical cause, and passionate commitment come together, the results are simply inspiring,” she reflected, months after the event’s formal conclusion, “and the experience has said to us every day since, ‘Don’t ever forget, and don’t ever stop until we find a cure.’” Every two years in Washington, DC, JDRF hosts over a hundred children with type 1 diabetes, ages 4-17, representing all 50 states and the District of Columbia, who meet face-to-face with their elected officials. As ChairMom, Pam helped to organize and execute all aspects of this enormous undertaking, becoming the go-to person for the participating families. But Children’s Congress was only the latest in a long history of JDRF activities for the entire Edmonds family: Pam, husband, Frank, and children, Holland, 8, Allie, 6, and Spicer, 2. Holland was diagnosed with type 1 diabetes in New York City soon after her second birthday and just days after 9/11/01. Her parents knew nothing about diabetes, and they remember their first few days and weeks as “being in the twilight zone.” But when they reached out for help, “JDRF was there,” says Pam. The family has participated in Walks (setting fundraising records), Galas, and many other JDRF programs from the beginning—and Pam and Frank continue to be active volunteer leaders in the New York and Central Virginia Chapters—but their most rewarding experiences occurred over the last three years, as they became increasingly active in the organization’s national Government Relations program. In 2005, Holland was selected as a delegate to that year’s Children’s Congress, where meeting so many other children with diabetes buoyed her spirits. Since her family’s move to Virginia in 2006, she has had no schoolmates or friends with type 1, so returning to Children’s Congress as the 2007 ChairKid was a high point in her young life. Back at home in Charlottesville, the Edmonds have continued their Children’s Congress responsibilities by making sure the delegates and their families participate in the followup grassroots Promise to Remember Me campaign. With a goal of achieving at least 400 meetings with their members of Congress in their local districts, the campaign’s top 2007-8 priority is renewal of the NIH’s Special Diabetes Program, which currently provides 35% of all federal support for type 1 diabetes. Last year, JDRF advocates succeeded in convincing over 260 House members and more than 60 Senators to sign a letter seeking increased funding for type 1 research. JDRF Government Relations has also played a vital role in developing the JDRF Artificial Pancreas Project and in 2007 made great progress in paving the way for approval for new continuous glucose monitors and other ciritical new devices through public and private health insurance plans. Pam says that while the fight for the cure has always been a “24/7” family concern, their Children’s Congress experiences made them realize that “it isn’t just about our chapter, but everyone’s chapter and every corner of the country and the world.” The Edmonds keep up with the other Children’s Congress families through letters and e-mail. “I’ve received messages from some of the older delegates telling me they had come to Washington begining to feel down and even defeated by their daily routine, but came away with a new resolve to accomplish their dreams, and with renewed hope for the future,” Pam reports. “That’s as uplifting to us as anything you can imagine.” 24 25 In for the Long Haul Ernie Herrman E rnie Herrman, President of Marshalls, has been personally touched by diabetes. His mother, who has type 2 diabetes, ended up in the hospital recently with kidney failure. “It’s hard enough when adults have to deal with this disease,” he says, “but I can imagine how devastating it is for children with type 1 and their parents. And it rears its head in such a sudden way in families.” But he says his main connection to diabetes is through the Marshalls partnership with JDRF. “After fourteen years, JDRF is part of our company’s DNA,” he says. “It’s a cause where we all try to do our part —from our management and marketing teams in the home office to our store associates in the field—and we hear ‘thank you’ from JDRF supporters in our stores every day during our fundraising campaign. That gives us a sense of pride and accomplishment.” With more than 750 stores in 44 states, Marshalls is one of the nation’s largest off-price family apparel and home fashions retailers. And through their teamwork and dedication, Marshalls employees and customers have raised more than $12.5 million for diabetes research, making the company one of JDRF’s top three corporate fundraisers. The partnership began over 14 years ago when Marshalls began a sneaker campaign in three California districts. The initial sneaker campaign raised $22,000. Just three years later, Marshalls was raising $500,000 a year for JDRF. “Knowing that so many of our associates were involved, we decided to organize the campaign that became the national program we have today,” Ernie explains. By 2000, annual donations had soared, employee Walk teams flourished, and many Marshalls employees began participating as local chapter volunteers and leadership. Last year, an in-store marketing campaign further increased customer awareness and participation, resulting in even more significant donations. “The fact that the initial efforts of a small percentage of our stores led to over $12.5 million in donations has had great impact on who we are as an organization,” Ernie says. “It’s a reminder that we are a collection of real people who can make a real difference.” Recently, Marshalls selected JDRF as one of its three cause partners. “It’s our way of committing to our communities now and in the future,” says Ernie. “We have long believed that a company must give as well as receive; our entire business model was founded on this principle.” Ernie notes that JDRF was initially selected because of its meaning to Marshalls employees and their need to be part of something beyond the job, “but JDRF will continue to be a key cause partner because of its meaning to the communities we serve,” he says. “Diabetes is pervasive and devastating, and we are in the fight for the long haul.” 26 A Life’s Work In tribute to Beverly Berry 1942-2007 A n inspiration to many, Beverly Berry taught kindergarten children when she was in her 20s, went on to have two children of her own, and loved and respected the wonder of young people all her life. And in the fight for all children and families dealing with type 1 diabetes, she created an enduring legacy. In 1982, Beverly collaborated with her husband, Ray Berry, in establishing the first The Fresh Market store in the couple’s hometown of Greensboro, NC, and she remained a guiding hand as it developed into today’s fastest-growing specialty grocery store chain in the United States. But it was her courage in fighting diabetes and her family’s single-minded devotion to finding a cure for that may remain her most indelible life’s work. Diagnosed with type 1 diabetes at age 31—when the couple’s daughter, Amy, was 3, and their son, Brett, 5— Beverly struggled to keep her disease under control, eventually developing serious complications. But the family only grew stronger and even more resolved to make a difference. In 1994, the Berrys joined the newlyfounded JDRF Piedmont Triad Chapter, over the years making personal donations, participating in the chapter’s Walk and other events, and advising the chapter on corporate fundraising and development. “I wasn’t thinking about a cure for me,” Beverly said in 2005, “but for the many children who will get this disease.” Beverly not only inspired family philanthropy, she also inspired The Fresh Market to become passionate JDRF supporters. For 13 years, The Fresh Market has held annual its annual Sidewalk Sale, a retail event selling hot dogs and root beer floats to benefit JDRF. The partnership has now expanded to include JDRF Sneaker sales and a variety of other fundraising events in all 77 stores across the Southeast and Midwest United States. With a 30 percent fundraising growth in 2007, The Fresh Market has raised a cumulative $1 million for JDRF. “JDRF is the focus of our philanthrophy,” says Michael Barry. “That’s who we are, and that’s who we’ll continue to be.” During the last five years of her life, Beverly also struggled with ovarian cancer, which affected her diabetic control. Yet her strength of purpose never failed. In July, 2007, Beverly acted as master of ceremonies at The Fresh Market’s 25th anniversary celebration, which benefitted JDRF. Later in the year, Michael Barry commented on her fighting spirit and the role model she had become. “With Beverly’s inspiration over the years, more and more of our corporate team, employees, vendors, and customers have come to understand and embrace the cause as their own, and they come through for us and for the cure.” Beverly Berry once said that her family’s and the company’s commitment to finding a cure overwhelmed her. “I’m inspired by the thought that one day diabetes will exist only in history books,” she said. JDRF remembers Beverly Berry for her caring, her generosity, and her courageous approach to life. 27 Donor Support JDRF thanks the individuals, families, foundations, and businesses listed on the pages that follow in their support of JDRF and research leading to a cure. 28 Corporate Donors $2,000,000 and above Ford Motor Company Cartoon Network and Turner Network Sales $1,000,000 - $1,999,999 Advance Auto Parts Hy-Vee, Inc. Marshalls Roche Diagnostics Corporation Stop & Shop Supermarkets Walgreens $500,000 - $999,999 Bloomingdales Coca-Cola Enterprises, Inc. Delta Air Lines Discover Financial Services Tops Markets UBS Financial Services Wawa $100,000 - $499,999 Abbott Diabetes Care Alberto Culver Products Albertsons, a SuperValu Company Albertsons, LLC Aldridge Electric Allscripts Healthcare Solutions American Airlines Amini’s Home, Rugs and Game Room Amylin Pharmaceuticals Anheuser-Busch Companies Aon Corporation Arizona Diamondbacks Bandy Carroll Hellige Advertising Bank of America Bayer HealthCare BD Medical - Diabetes Care Belk Inc. Bimbo Bakeries/Oroweat Bon Secours Richmond Health System Boston Marriott/Copley Place BP America Carolina Restaurant Group/Wendy’s Carowinds Casey’s General Stores Cash America International, Inc. Cavalier Telephone Cedar Fair Charity Partners, LLC Cingular Wireless Cisco Systems, Inc. Clear Channel Outdoor Coca-Cola Foundation DaimlerChrysler Assembly North Dell Inc. Edward Jones Eli Lilly and Company Ericsson Exelon Farmington Savings Bank FelCor Lodging Trust Fox 25/WFXT- Boston General Motors Corporation Halloween Adventure Harman Management H-E-B Grocery Company Integrated Marketing SOLUTIONS Intercontinental Hotels Group Intuit Kohl’s Department Stores Laredo National Bank LifeScan, Inc. Lincoln Electric Holdings, Inc. Mazda Motor Corporation McDonalds Medical Employment Directory Medtronic Minimed Meijer Inc. Melvin S. Roos Co., Inc. Mesirow Financial Monsanto Company Nationwide NBC5 Chicago New York Hospital Nortel Novo Nordisk Old Orchard Brands LLC Pathmark Pella Corporation Pepsi-Cola Company Pfizer, Inc. POAT (Police Officer Assistance Trust) ProHealth Care Pulaski Bank QUALCOMM Incorporated Quick Chek Food Stores San Diego Padres/Moores Family Sanofi-Aventis Pharmaceuticals Scientific Atlanta, A Cisco Company Sigma-Aldrich Corporation Silpada Designs Solution Consultants Sonora Quest Labratories Sony Computer Entertainment America SonyEntertainment Starwood Capital Group Starwood Hotels and Resorts Worldwide, Inc. Stillwell-Hansen, Inc. SWAT-Fame, Inc. Synergy Worldwide Texans Credit Union Texas Instruments, Inc. The Carroll Companies The Fresh Market The Meltzer Group The Sherwin-Williams Company The Thomson Corporation Union Pacific Corporation UnitedHealthcare-Midwest UPS Foundation USS Posco Wells Fargo Bank Wheel and Sprocket Williams/Gerard Productions WPP 29 Major Donors We would like to express our deep appreciation and recognize our friends who in FY2007 so generously invested $10,000 or more in new gifts and new pledges to our core programs for the JDRF International Global Campaign, From Research to Reality: The Campaign to Accelerate the Cure for Diabetes. Thank you. Outright gifts and pledges made between July 1, 2006 and June 30, 2007 $1,000,000-$4,999,999 Anonymous (2) Estate of Helene Alley in Memory of Theodore Whitlock and Theodore Whitlock Jr. The Benaroya Family McDonough Family Foundation Mr. and Mrs. David Novak Marianne and Roy Smith Mr. and Mrs. William T. Young, Jr. $500,000-$999,999 Anonymous Genentech, Inc. Paula and James McDonald and Ashley and Jeff Taylor John Spencer, in memory of Richard Spencer $100,000-$499,999 Anonymous (3) Abbott Laboratories Mr. and Mrs. Steve Altman The Bagwell Family (Maurine, Lisa and Kris, Dorinda and Kurt) Estate of Helen Balcerzak Penny and Bob Barnhill Bruce J. Bergman Janet L. Bergman Blistex, Inc. Estate of Betty Marie Boerum Geraldine and G. Thomas Borger Civil Society Institute Irene and Seymour Cohen Janice and Robert Compton Dennis and Cindy Connelly, Connelly’s Diamond Gallery and The Nemith Family, Nemith Motor Corporation The Cooper-Siegel Family Foundation J. Laurence Costin , Jr. Estate of Raya Cowan Henry D’Auria Lawrence J. De George and Florence A. De George Charitable Trust EMWIGA Foundation Ronne and Alan Fisher The Ella Fitzgerald Charitable Foundation Laura L. and Robert T. Fraley Frechette Family Foundation The James A. Gammon Charitable Foundation 30 The Harvey S. Gitlin Family Foundation Estate of Florena F. Henk Ethel Hoffman Hurlbut-Johnson Charitable Trusts Laurie and Michael Jaffe Mr. Jeff Jensen Ron Jensen Charitable Lead Annuity Trust Estate of Melvin C. Kelly, Jr. Randy and Ken Kendrick The Lincy Foundation Mr. and Mrs. Ure Kretowicz Karen and Herbert Lotman The Lowdon Fouondation Aline and Alfred Martinelli Phyliss McGovern Beth and J. Barry Mitchell Mr. and Mrs. Steven F. Norman Estate of Mary Camp Parks Nathan Patterson Lorna and Gary Pederson Melinda and Rick Poulton Estate of Mary Powers Estate of Robert M. Reininger Bobbi and Robert Reitzes Estates of Julian and Esther Rossnick Pam and Bill Sagan Holly and David Sherr R. Craig Smith Mimi and Barry Sternlicht Laura and Todd Templeton The Thomas Foundation Triad Foundation Glen and Trish Tullman Estate of Thomas L. Turnblom University of Illinois Patricia and Daniel Wagner The Wattles Family Foundation in Honor of Conner Wattles Sharyl and John Weber Wendy’s Estate of Tracy Loftis Estate of Shirley Mackey McDonald Automotive Group Lisa and David Miniat/Ed Miniat Inc. Estate of Kathryn E Moyer Daryl and David Nelms The George Polli Foundation Trizec Properties Inc. Eve and James Tyree The Woodbury Foundation $50,000-$74,999 Anonymous (2) Joan and Neal Allen Allied Karen and Herb Baum Becton Dickinson Bluegreen Corporation Ann and Rodger Call Karen and Steve Compton John and Joette Cook Mr. and Mrs. John Creelman Cynthia and Mark DeTrempe Brady Exber Fraternal Order Of Eagles Debbie and Tim Gardner Janice and James George GlaxoSmithKline Good Times Burgers and Frozen Custard Philip Green Heather and Micheal Greenbaum Patty and Chip Halverson Richard and Jean Harrington Hawn Foundation, Inc. Edward Heil Eileen and Mike Hendren David Herro and Jay Franke Mr. Timothy Hoiles Howard Family Foundation IPA Charities, Inc. Mr. and Mrs. Paul Jacobs Marjorie and Maxwell Jospey Foundation Donna and Steven Katz Don and Donna Kelleher Jennifer and Scott Keller Jerry and Bonnie Kelly Keyspan Michael Kluger In memory of John Kouris Melissa and Bob Laskey Judy and T. Scott Leisher David and Niki Levy The Lucas Family Foundation Jan and Dennis McGlone McKinney-Geib Foundation Vickie and Bob Mercer Joanne and David Mullen Barbara and Thomas Neal The Northern Trust Company Dejan Perkovic Chris and Cathryn Perry, in honor of Cathryn Catherine and John Peterman Karen and Jeffrey Peterson Family Foundation Mr. and Mrs. Arnold Petsche Mr. and Mrs. Roy Polatchek J. B. and M. K. Pritzker Family Foundation Joan and Michael Rich Patrick and Shirley Ryan Sage Hospitality Resources The Gary Saltz Foundation, Inc. Marlene and Bruce Saltzberg Mr. and Mrs. Alan Schroder, Sr. The Peter Jay Sharp Foundation Frank Sica Connie & Marc Sigel/ elements Boutique Jack Smith Thomas & Mack Company Wachovia Wagner Equipment Marlene and Larry Wald Bob and Kay Welsh Wendy’s Pisces Foods The West Endowment Mr. and Mrs. Joe White Elizabeth Mily and Ed Zwilling $25,000-$49,999 Anonymous (6) Anonymous Fund of the Greater Houston Community Foundation Mrs. Audrey S. Abbott Dr. Miriam & Sheldon Adelson Charitable Trust Kathy Albert Ann and John Amboian , Jr. AmerisourceBergen Bain Capital Childrens Charity $75,000-$99,999 Anonymous (2) Ben Curtis and the Tavistock Foundation, Inc. Estate of Hilda Dondero Estate of Roberta M. Hamblin Stephen Hanson D. Scott and Pamela Kroh Major Donors Baltimore Orioles Mrs. Charles Barber and Mrs. Laura Fraley Angela and Gregg Bartlett BD Technologies Mark Behan, Behan Communications, Inc. Richard and Susan Bingham Fund Shannon and Rik Bonness Debbie and David Bossy Bresler and Reiner, Inc. Robin and Elliott Broidy Mr. and Mrs. J. Mahlon Buck, Jr. The Bugas Fund Mary Elizabeth and Jeffrey Bunzel Cadbury Schweppes Americas Beverages Mr. and Mrs. Chris Callero Nancy and Joseph Carey Margo and John Catsimatidis Cerner Corporation Roy R. Charles Charitable Trust The Rhoda and David Chase Family Foundation, Inc. Children’s Diabetes Foundation at Denver CIGNA Corporation Brett and Sheryl Clanton Marty and Bruce Coffey Elsie T. & Josephine Colombo Charitable Trust Community Bank of Colorado ConAgra Foods Terry and Peter Conn Katherine and Graeme Crothall MaryAnn and Greg Cull Mark and Molly Curry Mr. and Mrs. A. J. D’Amato The Dash To Cure Diabetes, Inc. The DeBardeleben Foundation Caroline and Dirk Degenaars Dematic Corp. Roberta and Steve Denning Diermeier Family Foundation Michael and Joan DiTullo James Dobson Mr. and Mrs. Skeets Dunn Estate of Ilse Besman Earl Echo Valley Foundation Paul Edgerley EDS Electronic Tax Center Stevie and Karl Eller Equitable Resources Jane and Andrew Evans Extended Care Information Network Joel and Marsha Faber Mic Feld Judy and Richard Feldstein Tom Ferguson Shelly Fisher and Dr. Scott Fisher Donna and Mort Fleischer Jere and Anne Fluno Jere Fluno in memory of Austin Melvin Larry and Cheryl Franklin Freishtat Foundation The Funny Bone Comedy Club Marcel Gamache and Bette Lee - Gamache Murry Gerber and Cheri West Stacy and Chip Gerber Granite Nancy and Donald Gray The Vincent E. Greco Foundation Gulton Foundation, Inc. Mr. and Mrs. David P. Halle, Jr. Ellen and H. Edward Hanway Randie and Robert Harmelin Hewitt Associates Sandy and Michael Hecomovich John S. Hilson Family Fund, Inc. Kit and Robert Howard Mr. and Mrs. Terry H. Hunt Shawn and Deidre Hunter Elizabeth McCaul and Frank Ingrassia Intracoastal Realty Corporation Mr. and Mrs. Masood Jabbar Greg and Ellen Jordan Mr. and Mrs. Norm Kallan Linda and Buddy Kaufman Wendy and Mavis Kelsey, Jr. Estate of E. Virginia Kennedy Kenny Construction Company Key Investment Florence and Chester Kolczewski Peter LaPietra Gilda and Murray Lappe LaSalle Bank The Lawton Family Fund The James Annenberg La Vea Charitable Foundation Hilary Valentine and Don Listwin Estate of Joseph T. Lopreste Edward and Kathy Ludwig Brian and Tara Luing Kelly and Michael Mahre Christine and David Martinelli Stuart and Flora Mason Massapequa Lacrosse Club Helen and William Mazer Foundation John McConnell Eugene and Lisa McGovern Phyllis McGovern Laurie and Kevin McGraw Harriet and Stanley Meyers Pauline and Ronald Miniat Neal Miranda Jennifer Moores Alan Morris and Pia Exber-Morris Mike Mullen Leah and Leo Mullin Nalco Foundation John H. & Ethel G. Noble Charitable Trust Nuveen Investments, Inc. Natalie and Paul Orfalea, Orfalea Family Foundation The Alfred O’Sullivan Memorial Fund A.J. and Sigismunda Palumbo Charitable Trust The Parthenon Group Loretta and Doug Patterson Penn Payne and Dr. Net Payne James Penrose Pepper Construction Company George Perkins, Jr. Estate of Alma Peterson Pfeiffer Foundation PNC In honor of Julie Polatchek Estate of Mary Powers Linda and Richard Price The Price Family Foundation Queensboro Hill Jewish Center Anne and Stephen Rader Rancho Santa Fe Women’s Fund Ginny and Marty Reagan ReedSmith Estate of Rhea Reynolds The Reynolds Family RLJ Companies, LLC Cathy and Tony Rogowski Friends of Cathy and Tony Rogowski Mr. and Mrs. Scott C. Rolles Mrs. Jean E. Rolles Debra and Kevin Rollins Barbara and Duke Roos Jamee Moroney and Richard Rosenberg Toby and Michael Rozen S&D Coffee Nathalie and Ted Sann Margaret and Robert Schafer Estate Of Harold W. Seele Candy Selig and Dr. Robert Selig Ann and Stephen Sherman Neil and Lenore Sherman Alan & Lisa Shusterman Family Fund Ellen and Morton Silver Carolyn and Peter Slocum Charlotte and Brad Smith C.D. Spangler Foundation Mr. and Mrs. Doug Speddiing Philip Stapleton Marianne and Roger Staubach Denise and Thomas Stern Mark Stevens Susan and James Stuart, Jr. Mr. and Mrs. Richard Thomas Time Warner Cable, Inc. Helen F. Toal Charitable Remainder Trust TransAm Trucking, Inc. Robert Trout Charitable Remainder Trust Marie B. and Richard G. Unnerstall Variety Club ViraCor Laboratories Judith and David Wachs Family Foundation The Wackenhut Corporation George Walker Greg and Sandra Walton Ward Lay Elyse and Ken Waters Butch and Fran Weaver Susan Mott Webb Charitable Trust Will Weinstein Estate of Mary Wiedner The Woodbridge Company Limited Donald Woods Mr. and Mrs. William Woods Monica and Robert Yolles Beverly and Bruce Young The Zappacosta Family Natasha and Dirk Ziff $10,000-$24,999 Anonymous (14) AAR Corp ABC Refrigeration & Air Conditioning, Inc. Lisa and George Abd Access Industries Accor North America Mr. and Mrs. Danny Adkins The Aeroflex Foundation Aimbridge Hospitality Akin Gump Strauss Hauer & Feld Allan, Seena & Laura Starr Mr. and Mrs. Dick Allen Joanie and Steven Alley 31 Major Donors David and Lisa Alpert Alro Steel Foundation American Needle, Inc. Christine and John Andrie Animas Corporation Anschutz Entertainment Group Helene and Allen Apter Foundation Arenz Foundation Jennifer and Joseph Armetta Rosalind and John Ashkar Ateeco Inc The Atlantic Philanthropies The Sandra Atlas Bass & Edythe & Sol G. Atlas Fund, Inc. Rick and Verna Austin Gene Axelrod, Beverly Hills Country Club Rick and Cathy Baier The Bantle Charitable Foundation Dr. Michael Barber David Barnes, Houlihan Lokey Howard & Zukin Donald Barnes Barrasso Usdin Kupperman Freeman & Sarver, LLC Laura and James R. Barrons Leslie Basnight Mr. Richard Bassuk Mary Lee and Richard Bastin Patrick Baumgarten Baxter Credit Union Baylor University Medical Center Beacon Realty Trust Bearing Point The John and Frances Beck Family Foundation Jeff and Sharon Becker The Dan M. and Julia B. Belden Charitable Fund Mr. Alan Benaroya “Barbara and Terry Bendrick Debbie and Brent Berge Nancy and Craig Berge Mr. and Mrs. Steven Bergstrom Linda and Charles Berry The Lowell Berry Foundation George Bilicic Dennis Black Gail T. Blair Robert Blashek, O’Melveny & Meyers, LLP Mr. and Mrs. Marvin Blecker Gary Block Susan and Jonathan Bloom BNP Paribas Craig Bolles Mr. and Mrs. Philip Bosl 32 Boston Scientific Corporation The Boston Consulting Group Bovis Lend Lease Inc. Darci and Patrick Bowen Crandall and Erskine Bowles Sue and Jim Boyd Thomas P. Brobson and David A. Brady Darryl and Heidi Brandon Gerard and Emily Branka Ms. Karin Von Ullmann Brauweilerweg Mr. and Mrs. Hal Brice Tony and Amy Briney Edye and Eli Broad, Eli Broad Foundation Linda and Todd Broin Brothers Air & Heat Bucks/Montgomery Homebuilders Charitable Foundation Loraine and Gary Budke The Bulkley Foundation Trust Julie and Ryan Burrow The Burstin Family Lynn and Chad Buxton BWAB, Inc. Cacoosing Family Charitable Foundation Cadwalader, Wickersham & Taft Mike Cahill, City National Bank Gloria and Louis Cairo Wendy and Brad Calloway Jeanine and James Camaren Ann and John Campbell Mark and Marianne Campbell Cannon Business Soluntions Captive Resources, LLC. Carita Foundation Karen Carney Estate Of Joanne Caron Caroselli Beachler McTiernan & Conboy William Caroselli and Dusty Elias Kirk Harry Carr Mollie and John Carroll Beth K. and F. Gray Carter Kim and Carl Casale Karen and James Case Estate of Constance Casner CentiMark Roof Systems Cereal Food Processors, Inc. Gary Chadwick Chapman Family Fund Charles Schwab Richard and Maxine Charlton Peter Chernin, FOX Entertainment Group Chiefs’ Children’s Fund Children’s Hospital of Pittsburgh Christensen Charitable Foundation, Inc. CIBC World Markets Corp. Citigroup Tim and Toni Clark Clayco Coastal Spine, P.C. Shiva and Keating Coffey John Cogan Cognos Bradley Cohen, Cohen Asset Management Cohen & Grigsby, PC Max and Rita Cohen Mr. and Mrs. Brad Cohen Patricia Moncada and Eric Cohen Sandra and Sheldon Cohen Samuel and Nancy Colella Commerce Bank Competive Edge Computer Associates Mr. and Mrs. Michael Connellan Rick and Lerri Cooper Valerie Cooper Ann and Arthur Cornfeld Cortina Sports Jill Cossman, Greenberg Glusker Kennedy Covington Penney Finkelman Cox, Sony Pictures Diana and George Coyne The Gerald and Daphna Cramer Family Foundation, Inc. Wendy and Tom Cramer Tammy Crawford Craig Cuvelier Marvin and Lauren Daitch Ed Darken Mr. and Mrs. Ronald Davies M. Marie Davis Jones Day Kelly and Robert Day Sahan Daywi Foundation Lynn Forester de Rothschild Patricia and Richard Deary Mr. and Mrs. Victor DeBellis Deloitte & Touche, LLP Jack Devine Foundation Estate of Joanne Dew Lieutenant Governor David Dewhurst Diabetes Shoppe Sean and Suzanne Doherty Tama Antonia Donaldson The Elliott Donnelley Family Trust Diana and Robert Doyle Jim Durree, Avery Dennison Eunice L. Dwan 1991 Irrevocable Trust Bijen and Christopher Dyrek Jodie and John Eastman Katama and Jay Eastman Sandra and Allen Ecker Lori and David Edmark Mr. and Mrs. Frank S. Edmonds Jr. EDS Company Edsal Manufacturing Co. Inc Herm and Lia Edwards Estate of Ralph Edwards El Pomar Foundation Mr. and Mrs. Jeff Elghanayan Elizabeth Arden, Inc. Bonnie and Dennis Ellman, Greenberg Glusker Renee, Rebecca and Richard Elmen Foundation Janet and Arthur Emerson Empire Distributors Charles and Pam Engelken Energy Association of Pennsylvania Philip Epstein Equity Office Properties Essilor Laboratories of America Mr. and Mrs. Andrew Evans Susan and Brad Evans Experian Marcia and Joel Faber Steven N. Fayne Mr. and Mrs. Geoff Fearns Tamara and Patrick Ferry Fidelity Investments Norman Fields Ralph Fink Mr. and Mrs. Doug Firebaugh First Commonwealth Bank FirstEnegy Foundation 1stBank Greg Fisher Martin and Michelle Fisher Joseph A. Fleck Mr. and Mrs. Tim Fleet Dara and Ragan Folan Edsel and Cynthia Ford Foxboro Against Diabetes The Samuel J. and Connie M. Frankino Charitable Foundation Jean and Curt Feuer Joel and Julie Friedlander Fullenkamp, Doyle & Jobeun Fuller Custome Homes John and Mary Glynn Furlong Major Donors Gay and Stanley Gaines Mark Galis Ellyn Garofalo, Liner Yankelevitz The Gatherer Family Foundation GCG Financial, Inc. GE Health Care Technologies Mary and James L. Geisman Richard L. Gelb Fund of the Lawrence M. Gelb Foundation, Inc. Anne and Gary Gentles Bob and Gail Germain Matt and Marysia Gerson Julia and Mark Gerstein Gibbins, P.C. Connie and J. David Gibson, III Gibson Technologies Mr. and Mrs. J. David Gibson, IV John Gilbertson Gillespie Auto Group Jane H. Gilmer Mr. Merle Gilmore Giuliani Partners Mrs. Esther Glazer Gleason & Associates, PC Mr. and Mrs. Mark Gleiberman The Josephine Herbert Gleis Foundation The Gloor Law Group LLC Jonathan and Eliose Goldman Patricia and Bernard Goldstein Amana Golf Linda and Raymond Gomberg Lois Gooch Goodrich Corporation Debbie and Stuart Gordon Michael and Loren Gordon The Gorham Family Charitable Fund Mr. and Mrs. Stanley Graber Joe Grady Fran and William Graham Linda and Robert Graham The Graham Company Dolly Graul Edith Dee Green Foundation Greenlee Partners, LLC Stan Greenspon Debra and Bruce Grewcock Michele and Doug Grewcock Donna Grogan Marcella and Irvin Grossack Rob and Sheri Guimont Gwynedd-Mercy College Chris and Cathy Haase Rita Haddow Hagan Foundation Monica and Paul Hagedorn Craig and Barbara Hakkio Halliburton Clay Hammerstein, CB Richard Ellis The Hamrick Family Foundation, Inc. Harmelin Media Jim and Janet Harris Harvard Pilgrim Health Care HSA/ Commercial Real Estate The Helen G. Hauen Foundation Joy and Ralph Hauser Walt and Judy Havenstein William & Roberta Hayes Charitable Remainder Trust Kassy and Joseph Helme Herbst Gaming, Inc. The Hershey Company Hickory Printing Group Highmark, Inc. Richard and Margaret Himelfarb Jim and Kathy Hipps Drs. Melissa and Guy Hoagland Chris Hoffman Mr. and Mrs. Thomas Hoffman, Jr. The Hollinger Group Joseph and Diana Honet The Hoopis Financial Group Foundation Horizon Paper Helen Howard Donna and Charles Huffman Pamela and Roger Hull Donald Hultgren The Hunt Foundation Michael and Suzanne Hupy Mian Husain The Stewart Huston Charitable Trust Mary and Donald Hutchings I-80 Cosmopolitan Club IBM Illinois Road Builders Assoc Mr. and Mrs. David Ingber Joseph F. Intagliata Integrity Bank Interep International Tool Steel, Inc. Iowa Health IPSCO, Inc. Cindy and Jim Irvine Mr. and Mrs. Masood Jabbar Mr. and Mrs. James Jaqua Dan and Shelle Jensen Jochum-Moll Foundation Andrea Johnston David and Christine Johnson Laura and Jim Johnson Richard Johnson Ron and Karen Johnson The Tom and Edwina Johnson Family Foundation Donald and Nancy Jones Karin and Gregory Jones Valerie and Gregg Jones Mr. and Mrs. Damien Jordan Mary Pat and John Kagel Mr. and Mrs. Mike Kahn Robert J. Kahn Foundation Rosalia and Craig Kaintz Ilene and Andrew Kallman Carol and Edward Kaplan Nickelodeon Boris Karol Martha and Bruce Karsh Estate of Morton Karsh Michael Keating Paul Keglevic Kelley, Drye & Warren LLP Britta Bushnell and Brent Kessel, Kubera Portfolios KEW Realty Corporation Kristen and Taras Kihiczak, Kick Law Firm, APC Kilpatrick Stockton LLP Kimco Corp. Kristen Klint Mr. and Mrs. Mark Knorringa KPMG LLP Steven and Marilyn Kraft Frederick and Susan Kramer Janet and Theo Krapels Mr. Michael Krasny Alvin Kruse Ted and Ann Kurland Carolyn Labutka Mr. and Mrs. Marshall Laitsch Lisa and Hal Lamb Lynn and Paul Lattanzio Jonathan Lavine Paul Lazarre and Jennifer Ames Lazarre Reid Leggett Mrs. William Leslie Jr. Alan and Ellen Levin Estate of Sophia Levin Lanny Levine Joseph Levonas Joel Levy, Corday Productions Chuck Lewis and Penny Bender Sebring Sharron and Delbert Lewis Lexis Nexis Group Julie and Jason Lichtenstein Jim and Gloria Lighthizer The Larisa M. Ligon Trust Mr. and Mrs. Loren Lingenfelter Alene Lipshaw Jennifer and Alec Litowitz Patricia and Eric Lobenfeld Lockton Companies, Inc. George Loening Lormar Foundation Jacqueline and Richard Loynd Lozier Corporation Ms. Kimberly Lund The Lynch Foudation Carole and Robert Machiz Robert and Terry Madden Jerome Magner Maguire Properties Group Ms. Liz Smith Malick and Andrew Malick Mr. and Mrs. Bob E. Mallory Peter and Catherine Malone The Mantria Group, L.P. Ron and Angie Marcinelli Dan and Sue Marus Nancy Lurie Marks Family Foundation Barbara Donnell and Scott Markus Jane and Z Marshall Timothy Martin James and Susan Maslowski Massey Charitable Trust W. David and Mary Maxwell William Maxwell, PhD Wilbur May Foundation Jeffrey and Katina mayer Mayer Brown Rowe & Maw Mark and Anna Maynard Bryan Mazlish Robert and Lorraine Mazzarella Del and Dennis McCarthy Mr. and Mrs. Scott McCormick McCownGordon Construction, Inc. Kevin McCulloch Joyce and Charles McCullough Shippey and J. Walter McDowell Mr. and Mrs. Patrick J. McFeeley (Sr.) Mr. and Mrs. Patrick McFeeley (Jr.) Kim McGartland Francis and Helen McGrail McKamish, Inc. McKinsey & Company, Inc. William B. McLaughlin Charitable Trust MedStar Health Lillian Mejda Lance and Lissa Melber Shelley and Donald Meltzer 33 Major Donors Adele and George Merck Merisant US, Inc. Fred and Candy Merrill Merrill Companies Merrill Lynch Mr. and Mrs. Fred Merrill, Sr. Merritt Properties H. Conrad Meyer, III Marty and Randi Meyrowitz Microsoft Estate Of Mary Jane Mika Gary and Holly Mikula The Miliken Family Foundation Milken Family Foundation Bella Miller Mr. and Mrs. Eugene C. Miller, III Dr. and Mrs. Irving Millman Janis and Jon Mills Sharon and John Miner Charlotte and G. Gilmer Minor, III Molly Shaffer and Paul Minorini George P. Mitchell Sharon and Vasu Mohan Victoria Mooney Moore & Van Allen, PLLC Elizabeth R. Moran Charitable Trust Mr. and Mrs. Eric Morris Mr. and Mrs. William Morrison Mphasis James Mulally, Capital Group Companies Charitable Foundation Sean Munster Michelle and Stephen Murphy Estate of Elizabeth Ann Murray Mutual of Omaha Heather and Bob Mylod Rebecca and Bill Nassikas James & Sally Nation Foundation National Amusements, Inc. Mrs. Beatrice Naumann Susan and Jim Nelson Mr. and Mrs. Mark Nemith Nestle Waters North America New Balance Athletic Shoe, Inc. New York Yankees Foundation Priscilla and Micheal Nicholas Peter and Teresa Nicholl Mr. and Mrs. Jack Nix John and Linda Nordin John Norheim Dellora A. and Lester J. Norris Foundation John Norris Nortel Jean Norris and Vincent Norton Novo Nordisk Pharmaceuticals NYS Dept. of Health Jane and Daniel Och Olde Stonewall Golf Club/Artifacts Terry and Lynn O’Leary Bill O’Malley O’Melveny & Myers LLP Edmond & Alice Opler Foundation Jody and Frank Osborn Tom Osborne Brendan and Jane O’Sullivan Estate of Gunnar S. Overstrom Bill and Norma Overton Carol and John Oxenreiter Debra and William Pabst, III Palm Beach Prayer Team Ministries, Inc. Tamara and Zoltan Papp James Pappas Jane Parker Parker, Laurie and Charlie Parker The Jack Parker Foundation Jack M. Parrish, Jr. Charitable Trust Paytime, Inc. Rick Pearson Susan and Doug Pearson In memory of Jules M. Perlberg to support the work of Victoria Prince, Ph.D., at the University of Chicago. Pepper Hamilton LLP Jeanene and Ford Perry Philadelphia Newspapers, LLC Bret and Nancy Pilney Pinnacol Assurance Elaine and Akiva Pipe Pitt County Memorial Hospital Polymedica Pongratz Enterprises, Inc. Art Pope Mr. and Mrs. Jim Portner John Powell Lisa and Doug Powell Presque Isle Downs Priarie Meadows Mr. and Mrs. Lev. H. Prichard, IV Principal Financial Group Purchasing Management International Pam and Simeon Pyne Pyramis Global Advisors Nina and Mitchell Quaranta, SWAT FAME Emily and Derek Rapp Lynn and Benjamin Rassieur III RBS Greenwich Capital Reed Smith LLP Reed Smith Sachnoff & Weaver Chris Reilly Theodore and M.Q. Reimel Steve and Mary Reintjes John and Lisa Reisman Kerensa and John Reiss Bobbi Reitzes The Renco Group, Inc. Nancy and Donald Resnick Rick Resterlli Cancer & Heart Foundation Rice Family Foundation Chris and Ginny Rich J. Jeffrey Riggs Tom riley Rob and Rosemary Roberto Robindale Energy Services, Inc. Mr. and Mrs. Joseph Rodriguez Tony Rodriguez Daniel Rogers Foundation Nancy and Richard Rogers Ropes & Gray, LLP Lois A. Rosenbaum Nancy Ross Cele H. & William B. Rubin Family Fund Pam Runge for Cassie Runge Timothy Ruth Ann and John Rutherford Mr. and Mrs. Michael Sabourin Colleen and Michael Saca Dave and Janice Sachs Terry Saltzberg Cheryl and Joseph Salvagne Robert T. Samuels Sheldon and Susan Sandler Mr. and Mrs. Thomas Sansone Mary Pat and Thomas Santel Dorothy M. Sarni Jay and Janis Scaramucci Mr. and Mrs. Joel Schaller Anne and Robert Schank Diane Fahey and Joseph Schiffhouer Diana and Steve Schiro Barbara Stewart and Warren Schloat Cheryl and Michael Schmid Mr. and Mrs. Eric Schoonveld Jeffrey Schumacher Jeanne and E. Christopher Schutt Lonnie Haymes Schwartz Estate of Elizabeth Scott Seaward Management Corportation Mr. and Mrs. Michael Seedman Paula and Ronald Seward Susan and William Shea Shearman & Sterling Jim and Lavonne Shedivy Mr. and Mrs. Neil Sherman Sherrard German & Kelly, PC Flip and Janet Short Larry and Janice Shulman Kathi and Bradd Siegel Siegel, David & Kathy Drs. Larry and Nancy Silverberg The Sidney Milton and Leoma Simon Foundation Eileen and Brian Simpson Mr. and Mrs. Andrew Singer Raymond Skilling Mr. and Ms. Greg Skjonsby Peter Smail Cheryl and Kevin Smith Melissa and John Smith Mr. and Mrs. Wayne Smith Mr. Greg Smith William C. Smith Smoker Friendly Gassamat Till and Todd Somers South Poing Hotel & Casino Anne and Bernard Spitzer Bill and Robin Spooner Springs Industries Richard and Ginny Srednicki Mark and Theresa Stagg William and Caren Stangel Bob and Connie Stanley Steel Fab Joanna and William Stein Mr. and Mrs. Michael Stephens Mr. Jeffrey Stern Jeb and Stephanie Stewart Jeff and Mary Stier Mr. and Mrs. John Stoner George B. Storer Foundation Meryl Streep Scotti and Luke Strockis Strong Pipkin Bissell & Ledyard, L.L.P. John and Liz Stropki Guy Miller Struve Studley, Inc. Sudler Property Management Michael and Debora Sullivan Joel Sussman, Jobar International, Inc. Linda and James Swearengen SWEET’N LOW BRAND ZERO CALORIE SWEETENER Greg and Kris Swetnam Mr. and Mrs. Wayne Swetnam Gene T. Sykes 34 Major Donors Susan Talbot Connie and Jeffrey Tarrant Mitch and Ellen Taube Dr. and Mrs. Francis B. Teague, Jr. Pam and Roger Teague Teammates for Kids Foundation Jane and John Tisdale Cynthia B. Tomlinson Foundation Mr. and Mrs. Bill Torres Paul Tosetti, Latham & Watkins, LLP Towers Perrin Mr. Brent Townsend Toys R Us Children’s Fund, Inc. Marci Eisenstein and John Treece Tritium Card Services, Inc Tina and Byron Trott Bonnie and Tom Trotta Tube City/IMS Corporation Tuccio Development Guila and Lash Turville United Conveyor Corporation United Fire and Casualty United States Steel US Bank Valentine and Kebartas Eileen and Keith Vass PGA of America and Scott Verplank Hollis and Chris Volk Volvo America Mr. and Mrs. Richard Wackeen Ruth J. Waggoner The J.E. and Mildred Waggoner Family Foundation Wade and Gena Walker Estate of Donald Fred Walker Estate of Lillian K. Walker Lisa and Neil Wallack Wal-Mart Foundation Thomas and Teresa Walsh Walsh & Nicholson Inc. Marla and Craig Wasserman The Terry K. Watanabe Charitable Trust Watkins & Eager PLLC Cindy and Robert Watts Margaret and Thomas Weekley Bob and Cheri Vander Weide Foundation Seymour and Jayne Weiss Estate of Joanne Weller Dr. and Mrs. E. Hunter Welles, III Gail and Chuck Welliver Wells Family Foundation, Inc. Wells Fargo Bank Robert and Kathleen Welsh Foundation Gloria and Robert Werth Patricia West West Coast Asset Management West Corporation Estate of Anna Mary West Michele and Thomas Whalen Bruce White Patty and Dan White Sharon and Michael White Mr. and Mrs. Jonathan Weiser Mr. & Mrs. Edward Wilbraham Jonathan and Tracie Wilk William Anthony Productions The Willmas Charitable Trust Janel and Charles Woldt Alexander Wolf & Son Rick and Treva Worth Ellen and Stavely Wright Brian Wruble and Kathleen Bratton Xerox Frances Yedlin Jeff Yingling Lisa and Jason Zeid Julianne and Todd Zeile, Green Diamond Entertainment Zemeckis Foundation Zurich American Insurance Co BETA Society Members Julie and David Abes Diane K. Adams Lisa Alejandre Tom and Joan Amabile Kris Bagwell Dr. Joshua Bardin and Dr. Carol Cheney Mike Battershell Clive and Bonnie Becker-Jones Dr. Richard Bingham Martin E. Birnbaum Linda and Lawrence Brongel Martha and William Bryant Sherry Burchett John and Florence Cassella Andy Childers Rita Cohen Nancy Cook Valerie Cooper Lauren Daitch Marvin Daitch Aila Dawe Nanette DeTurk Barbara Dinse Josephine Donaldson Jodi and Jeff DuFresne Peter and Elizabeth Ellison William M. Fine John A. Freeman Linda and Joseph Gardner Peter Gaston Karen Giambrone Esther E. Glazer Deborah Gokie Lois Gooch Claudia Graham Jessica and Warren Graham Greenspon/Goldstein Family Foundation Caroline and Dan Hair Whitney Holman Julius and Ruth K. Honig Deneka and James Horalek Barbara Hudson Andrea Hulke Kim Hutchins Rosalind and David Ingber Ron Isenhour Maryann Jacobson Dr. Kevin and Suzi Jones Sivia Kaye William Keller Hilda Kelly Charlotte Kidd Kelly and Mark Kindberg Diane M. Knowlton Kathy Koch Kathryn Little John Madsen Kelly and Michael Mahre Dorothea Mancke Dr. and Mrs. W.F. McGuire Dr. and Mrs. Hugh McLeod Dr. Donald and Harriet Meltzer Hannah Melvin Robert Mercado John Mercier Lori and Wayne Miller Dr. and Mrs. Irving Millman Sallie and Hugh Morrow Stephen Murphy Donald Namm Mrs. John Nettleton Cheryl Nickels Pearl and Kenneth Noreen Norma Novak Wendy and David Novak Truman and Naomi Palmer Steve and Jackie Pella Marian Pure Dr. Martina T. Richardson Stephen Riddell Jennifer and Dan Rodriguez David I. Roos Jr. Stephen L. Rosen Michael Charles Rothman Lewis Runnion Valerie and Matthew Scheibeck Kathleen and Gus Searcy Ronald Seward Cliff Smith Robert Smith Gretchen and Phil Stanislav Cheryl and Christopher Sullivan Allan Tanenbaum Judy and the late Dave Thomas Linda and Dave Tobin Lisa and Neil Wallack Joan and Fred Weisman Christopher and Moira Whitfield Nancy and Kenneth Winn Steve Winshel William and Johnina Woods in Loving Memory of John William Woods Lane Zbar 35 Stem Cell Research Fund CO-CHAIRS: MARY TYLER MOORE AND S. ROBERT LEVINE, M.D. The Juvenile Diabetes Research Foundation International wishes to express its deepest gratitude to the following members of the JDRF family. Through their tremendous generosity in the form of donations of $10,000 and up, the JDRF Stem Cell Research Fund, since its inception in fiscal year 2002 is now well over $17 million. The vision and leadership of these donors will ensure that the promise of stem cell research to contribute to a cure for type 1 diabetes and its complications will be pursued. Anonymous (2)* The Judith and Jean Pape Adams Charitable Foundation Alagem Capital Group Susan Alberti, AM*^ Mrs. Kathleen Albrecht and Mr. Pete McCormick Andrew Family Charitable Foundation Helene and Allen Apter Ares Management LLP Veronica Atkins Karen Barfoot^ The Bloom and Mittel Founding Families of the Greater Bay Area Chapter Quent and Inez Boyken William K. and Delores Brehm Broidy Capital Capital Guardian Trust Chartwell Charitable Foundation Dean and Shirley Chenoweth Clarity Partners Irene and Seymour Cohen* Comerica Bank Ken and Sherry Corday Thomas and Wendy Cramer Creative Arts Agency Alison and Richard Crowell Jaime Davila Lawrence J. and Florence A. DeGeorge Charitable Trust* Danny DeVito and Rhea Perlman Eunice L. Dwan Charitable Trust EMWIGA Foundation Entertainment Industry Foundation Joel and Marcia Faber Allen Feltman and Arlene Jacobs, M.D. Mr. and Mrs. Simon C. Fireman First Republic Bank Marilyn and Dr. Gerald Fishbone Greg Fisher and Family The Ella Fitzgerald Charitable Foundation Jeanine Forman-Ham The Lauren Gatlin Stem Cell and Beta Cell Research Initiatives Fund Geffen Foundation James Gorton Greenberg, Glusker, Fields, Claman and Machtinger Clay Hammerstein and Family Michael Heine*^ Michael and Loretta Helfant Stephen and Roey Higgs*^ Hille Foundation Irell and Manella, LLP Frank and Sophia Jackson*^ Robert Wood Johnson IV Damien and Yvonne Jordan Marjorie & Maxwell Jospey, In Memory of Their Daughter, Jane Jospey Cobb Marjorie & Maxwell Jospey Foundation* WM Keck Foundation The Kennedy/Marshall Company Brent Kessel and Britta Bushnell Taras and Kristen Kihiczak Laurie and Alec Kouyoumdjian Gilda and Murray Lappe Latham and Watkins, LLP Eason and Ellen Leake The Lee Family Fund Lewis-Sebring Family Foundation Richard and Jacqueline Loynd The Joseph D. Maio Scholarship Fund Sharon and Tom Malloy Alfred Mann Fred and Susan Mardell Andy and Terry Marx Foundation Douglas Matheson- Illinois Tool Works Helen and William Mazer Foundation Brian McCarthy Michael and Kimberly McClain Charles and Aniela McCool In Honor of Allison McDonough McDonough Family Foundation* The Giles W. and Elise G. Mead Foundation Medtronic MiniMed Mr. and Mrs. Gary Millican, In Honor of Alexander Millican and In Memory of Roy E. Millican, Jr. Mary Tyler Moore and S. Robert Levine, M.D.* Jim and Susan Nelson O’Melvany and Meyers Bert C. O’Neal, In Honor of Lisa and Jack Reed and Elizabeth Shannon In honor of Kathy and Mark Papermaster, Kathy and Steve Papermaster and Gail Papermaster and Dave Mattson In Honor of Alexa Claire Pederson* Paramount Pictures Lea and Barry Porter PR 21 Mitchell and Nina Quaranta Steve and Anne Rader Mr. and Mrs. Jack Reed, Jr. Remy Investors Jamie and Anthony Ressler In Honor of Mr. and Mrs. David I. Roos, Jr. and Family, In Memory of Debbie Roos Hoppenfeld Jan M. Roswig Sheila Royles^ Renee and Robert T. Samuels* Scudder Investments and Deutsche Asset Management In Honor of Elizabeth O’Neal Shannon Elizabeth O’Neal Shannon and Jack Herbert Shannon In Honor of Mrs. JoAnn Shull and In Memory of Her Daughter, Candy Mrs. JoAnn Shull Mr. James M. Shure and Family Kelly and David Siegel Reagan Silber -Edge TV Sandra and Alan Silvestri Victoria Mann Simms Skadden Arps Marianne and Roy C. Smith* Sony Pictures Entertainment Brenda and James Souers In Honor of Barry and Mimi Sternlicht* Donations made in honor of William Sternlicht* Jim and Susan Stuart, Jr. TransAmerica Trench Shoring Co. Jami and Nicolaus Von Heidegger Warner Brothers Pictures Casey Wasserman Charles and Mary Jane Wick Cynthia Wick and Channing Gibson Doug Wick and Lucy Fisher David and Terry Wohlberg Mr. and Mrs. William T. Young, Jr.* Anne and Allen Zaring Julianne and Todd Zeile Robert Zemeckis–Image Movers * Gifts Made during Fiscal Year 2007 * Donor to the Nucleus Fund ^ Australia 36 Cure Therapeutic Pathways Autoimmunity Jensen Charitable Lead Annuity Trust Ron Jensen Charitable Lead Annuity Trust Susan Talbot Complications Anonymous Susan & Jonathan Bloom Elsie T. & Josephine Colombo Charitable Trust In Memory of Sarah Gaither— Dedicated to the Diabetes Complications Cure Pathway. Ninette Gaither, Humana, Inc. & Randy Gaither, Kroger Genentech, Inc. The Hamrick Family Foundation, Inc. Ilene and Andrew Kallman Dejan Perkovic Nancy and Rick Riley In honor of Janelle and David Shaffer Rebecca Trammel in Honor of Dick Trammel In Memory of Zoie Willeford Metabolic Control Anonymous (2) In Honor of BIOCOM—Dedicated to the Cure Pathway of Creating an Artificial Pancreas In Honor of Daniel & Annette Bradbury and BIOCOM - Dedicated to the Cure Pathway of Creating an Artificial Pancreas Thomas P. Brobson and David A. Brady The Bulkley Foundation Trust Roy R. Charles Charitable Trust In Honor of Northern Nevada Children by Rod Cooper and Granite Construction Company In Honor of Kathy Crothall Jack Devine Foundation Golf Tournament Renee, Rebecca and Richard Elmen Foundation Janice and James George Keith E. Greenspon Generously Supported by The Heilbrunn Research Endowment Fund In Honor of Kassy Helme Joseph and Kassy Helme supporting the work of Dr. William V. Tamborlane at Yale University on the Artificial Pancreas The Jackson Foundation In Honor of Ken Kendrick The Anna Alber Promise Light Award in Honor of Randy and Ken Kendrick George P. Mitchell Mr. and Mrs. Steven F. Norman Ellen Rothchild-Taube and Mitch Taube Robert and Renee Samuels In Honor of the Seedman Family Cynthia B. Tomlinson Foundation The Louis Vance Family in honor of Kathryn Vance Research Grant Bob and Kay Welsh supporting the work of Dr. William V. Tamborlane at Yale University on the Artificial Pancreas Regeneration Lawrence M. Gelb Foundation R. Craig Smith Anonymous Penny and Bob Barnhill Mark Behan, Behan Communications, Inc. Dennis and Cindy Connelly, Connelly’s Diamond Gallery and The Nemith Family, Nemith Motor Corporation In Honor of Michael and Joan Ditullo Leonard Dzielski The Ella Fitzgerald Charitable Foundation In Honor of Alyson Pitman Giles, President and CEO of Catholic Medical Center Eileen and Mike Hendren Drs. Melissa and Guy Hoagland in support of Dr. Doug Melton’s research at Harvard Kit and Robert Howard Illinois Joins Together for a Cure In honor of all the children and young adults from the South Central Texas Chapter who live with Type 1 diabetes In Honor of J. Barry Mitchell Vickie and Bob Mercer In memory of Jules M. Perlberg to support the work of Victoria Prince, Ph.D., at the University of Chicago. In Honor of the Petsche Family Rancho Santa Fe Women’s Fund In Honor of all our children and young adults in the South Central Texas Chapter who live with Type 1 diabetes JDRF Academic Research and Development Awards: A High Throughout Exploration Platform for Beta Cell Replentishment. Douglas Melton, PhD, Harvard Stem Cell Institute, Cambridge MA. Generously supported by Laura & Todd Templeton The Wattles Family Foundation in Honor of Conner Wattles Joe and Linda White In Memory of Lauren L. Youlden Replacement Angela and Gregg Bartlett, in honor of Alexa & Carys Bartlett Postdoctoral Fellowship Award In Honor of Marshall Bouldin, M.D. Diermeier Family Foundation Marjorie and Maxwell Jospey Foundation Los Angeles Gala Honorees Natalie and Paul Orfalea, George Schlatter, Annette Bening and Warren Beatty In Honor of Alexa Claire Pederson 37 Named Grants Program The Juvenile Diabetes Research Foundation International wishes to recognize and express its deepest gratitude to the following donors, who generously committed funds to underwrite specific research initiatives under our Named Grants Program. The program offers individuals, foundations and corporations interested in diabetes research an opportunity to be directly linked to specific programs, all of which target JDRF research priority areas and are critical components of the search for a cure for type 1 diabetes. JDRF Center for Mechanisms and Intervention of Diabetic Retinopathy at Pennsylvania State University Center Director: Thomas W. Gardner, M.D., M.S. Pennsylvania State University College of Medicine, Hershey, PA, USA Center Benefactor: Mrs. Marian S. Ware Center Friend: Ilene Alexander In Honor of Jim Tyree In Memory of Josephine B. and James E. Wilson JDRF/Beverly Berry Center for Immunological Tolerance in Type 1 Diabetes at the Harvard Medical School This Center is made possible by Amy and Michael Barry Center Co-Directors: Diane Mathis, Ph.D., and Christophe Benoist, M.D., Ph.D. Joslin Diabetes Center, Boston, MA, USA Center Patron: In Honor of W. Douglas Parker and America West Airlines, 2005 Living and Giving Award Honoree Center Sponsor: In Honor of Nancy Jones Center Friend: Jensen Charitable Lead Annuity Trust Marnie and Dave Near In Memory of Joni E. Templeton JDRF/Marian S. Ware Program for Islet Transplantation at the University of Pennsylvania Center Director: Ali Naji, M.D., Ph.D. University of Pennsylvania, Philadelphia, PA, USA Center Friend: In Honor of Rachel and John Schuler JDRF Center for Translational Research at the Benaroya Research Institute at Virginia Mason Center Director: Gerald Nepom, M.D., Ph.D. Virginia Mason Research Center, Seattle, WA, USA Center Benefactor: The Benaroya Family The Lee Family The Pryde Family Center Patron: Anne and Stephen Norman Center Friend: Katharine and Ralph Brindley The Jeff Johnson Family The Family of Braedon Miller JDRF Center for Beta Cell Replacement at McGill and University of Montreal Center Director: Lawrence Rosenberg, M.D., Ph.D. 38 Montreal General Hospital, Edmonton, Alberta, Canada Center Friend: Marsha and Aubrey Baillie BMO Financial Group Kenny Chankowsky Memorial Golf Tournament Bonnie and Terry Jackson JDRF Clinical Center for Human Islet Cell Transplantation at the University of Alberta Center Director: James Shapiro, A.M., M.D. University of Alberta, Edmonton, Alberta, Canada Center Patron: The Mr. and Mrs. Edsel B. Ford II Ford Motor Company Juvenile Diabetes Research Fund Center Sponsor: Alice and Russell M. Artzt Boston Pizza International, Inc. RBC Center Friend: The David and Molly Bloom Juvenile Diabetes Fund Paul A. Dickie and Glen Anderson Dickie Novo Nordisk Canada, Inc. JDRF Developmental Center for Immune Tolerance at the University of Alabama at Birmingham – grant ended 11/30/06 Center Director: Judith M. Thomas, Ph.D. University of Alabama at Birmingham, AL, USA Center Patron: In Honor of Maggie & Gordon Hartman, the Buford Family and the Halff Family Center Sponsor: Bernice Barstein Center Friend: Compass Bank Howard Industries, Inc. and the McCoy Family, in Honor of Hannah and Alexandra Turbeville Generously Supported by Lauren Parker JDRF Center for Islet Transplantation at University of California, San Francisco/ University of Minnesota Center Co-Directors: Peter Stock, M.D., and Bernard Hering, M.D. University of California, San Francisco, San Francisco, CA, USA Center Benefactor: Mr. and Mrs. William and Pam Sagan Center Friend: JDRF Silicon Valley Golf Classic and Celebration In Honor of the Steve and Cindy Rasmussen Family Jensen Charitable Lead Annuity Tryst Named Grants Program AUTOIMMUNITY In Honor of Jonathan P. Altman Career Development Award T Cell Receptor Repertoire and Antigenic Specificities of Early Insulitic Betacellautoreactive HLA-A2-restricted T Cells Teresa P. DiLorenzo, Ph.D. Albert Einstein College of Medicine, Bronx, NY, USA BD Consumer Healthcare Research Grant Genetic Regulation of T Cell Recruitment & Insulitis Progression in Type 1 Diabetes Jayne Danska, Ph. D. The Hospital for Sick Children, Toronto, Ontario, Canada Coca-Cola Enterprise, Inc. Career Development Award Genetics of resistance to immune medicated Beta-cell destruction. Clayton E. Mathews, Ph.D. Children’s Hospital of Pittsburg, Pittsburg, PA, USA The Robert and Janice Compton Research Grant, In Honor of Elizabeth S. Compton T Cell Specificity and Function in Type 1 Diabetes Dario Vignali, Ph.D. St Jude Children’s Research Hospital, Memphis, TN, USA The Mortimer and Donald Furtsch Memorial Research Grant Tipping the balance toward b-cell protection and regeneration to cure IDDM Xin Xiao Zheng, M.D., M.P.H. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA Casey Johnson JDRF Diabetes Research Fund Pediatric Endocrinology Training Award Training for Pediatric Diabetes Patient-Oriented Research Sheela N. Maage, M.D. Children’s Hospital of Philadelphia, Philadelphia, PA, USA In Honor of Ahmed Mahfooz Latif Regulation of CD4 T cell Islet Entry Dario Vignali, PhD St Jude Children’s Research Hospital, Memphis, TN, USA JDRF-NIH Bridge Grant In Memory of Conor Lighthizer Antigens Recognized by CD8+ T Cells in Type 1 Diabetes, Albert Einstein College of Medicine, New York, NY, USA In Honor of Peter McKenzie and Ted Kurland Research Grant Engineering donor pancreatic beta-islet cells to repel recipient T-cells Mark Poznansky, M.D., Ph.D. Massachusetts General Hospital, Boston, MA, USA In Honor of David and Peggy Sokol Research Grant PDL1-based rAAV-medicated immunotherapy for mouse islet transplantation Jide Tian, M.D. The Regents of the University of California, Los Angeles, CA, USA The Barry and Mimi Sternlicht Pediatric Endocrinology Research Fellowship Pediatric Endocrinology Research Fellowship Nicole Sherry, M.D. Colombia University College of Physicians and Surgeons, New York, NY, USA The Coca-Cola Foundation Career Development International Award F-2 Isoprostanes in Diabetic Renal injury Angel Montero, Ph.D. Emory University, Atlanta, GA, USA BD Consumer Healthcare Career Development Award Mechanisms Underlying Glucose Counterregulation in Type 1 Diabetes Rory J. McCrimmon, M.D. Yale University School of Medicine, New Haven, CT, USA In Honor of David L. Boren Role of Pericytes in Diabetic Retinophathy James Tomasek, Ph.D. University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA In Memory of Paul M. Cournoyer Research Grant ACE2 in diabetic nephropathy David Leehey, M.D. Hines VA Hospital, Hines, IL, USA Delta Air Lines Career Development Award Mechanisms of oxidative stress and vascular inflammation in diabetes Subramaniam Pennathur, M.D. University of Michigan, Ann Arbor, MI USA In Honor of Betsy and Kane Ditto Research Grant Natural History of Subclinical Diabetic Macular Edema Neil Bressler, M.D. Johns Hopkins University, Baltimore, MD, USA Ford Motor Company Research Grant Early Assessment of Diabetic Retinopathy Treatment Response by Functional MRI Bruce Berkowitz, Ph.D. Wayne State University, Detroit, MI, USA H-E-B Research Grant PTEN, Akt, Kinase Diabetic Nephropathy Goutam Ghosh Choudhury, Ph. D. University of Texas Health Science Center, San Antonio, TX, USA COMPLICATIONS A Future Without Diabetes Postdoctoral Fellowship Award 2006 Role of the Hexosamine Pathway in Renal/ Vascular Complications Diabetes Lauren Ball, Ph.D. Medical University of South Carolina, Charleston, SC, USA Advance Auto Parts Research Grant Sphingosine-1 Phosphate Prevents Vascular Inflammation and Diabetic Complications Catherine Hedrick, Ph.D. University of Virginia, Charlottesville, VA, USA The Best of Illinois Postdoctoral Fellowship Award Mechanisms of Nocturnal Hypertension in Type 1 Diabetes Donn Hogan, M.D. Northwestern University, Chicago, IL, USA 39 Named Grants Program In Honor of David and Clydella Hentschel Research Grant A framework for Acquisition and Deployment of Digital Imagery for Computer-Assisted Evaluation of Diabetic Retinopathy Helen K. Li, M.D. University of Texas Medical Branch, Galveston, TX, USA Marshalls Career Development Award The Roles of Chemokines in the Pathogenesis of Diabetes and Islet Allograft Rejection Reza Abdi, M.D. Brigham and Women’s Hospital, Boston, MA, USA In Honor of Sean Owen Postdoctoral Fellowship Award Mechanism of Diabetic Autonomic Neuropathy in a Type 1 Diabetic Mouse Model Yali Zhang, M.D., Ph.D. New England Medical Center Hospitals, Inc., Boston, MA, USA In Honor of Tops Markets, LLC A Future Without Diabetes Career Development Award Molecular Profile of the Human Diabetic Kidney Disease Katalin Susztak, M.D., Ph.D. Albert Einstein College of Medicine, Yeshiva University, Bronx, NY, USA UBS Research Grant AMPK and Mechanisms of Glucose Toxicity Neil Ruderman, M.D., D.Phil. Boston Medical Center, Boston, MA, USA Research Grant Generously Supported by an Anonymous Donor Developmentally shifted liver cells as a cellreplacement therapy for autoimmune diabetes Sarah Ferber, Ph.D. Sheba Medical Center, Tel-Hashomer, Israel Advanced Technologies for Cell Replacement Therapies in Diabetes Generously Supported By: Friends of Illinois Unite for Hope and Progress Northwestern University Dance Marathon Advanced Technologies for Cell Replacement Therapies in Diabetes Kaufman, Dixon B., M.D., Ph.D. Northwestern University Medical School, Chicago, IL, USA H-E-B Research Grant Preventing Beta-Cell Destruction Roger Unger, M.D. University of Texas Southwestern Medical Center, Dallas, Dallas, TX, USA In Honor of John Hopkins, R. Ph. and Rocky Mountain Health Plans Research Grant Use of Hematopoietic Stem Cells for the Regulation of Autoimmune Diabetes Ronald Gill, Ph.D. University of Colorado Health Sciences Center, Denver, Co, USA Vickie & Robert Mercer Novel Pathways to Expansion of Functional Beta Cell Mass Christopher B. Newgard, Ph.D. Duke University Medical Center, Durham, NC, USA Chris and Cathryn Perry, in honor of Cathryn Inhibition of Beta cell loss by surviving gene targeting Rachel Altura, M.D. Children’s Research Institute, Columbus, OH, USA In Honor of Alexa Claire Pederson Enhancement of ES Cell Differentiation Towards Endoderm using RNAi Miguel Ramalho-Santos Ph.D. The Regents of the University of California, San Francisco, USA Jeffrey and Karen Peterson Family Foundation Signals Governing Stem and Islet Progenitor Cell Growth and Differentiation Dr. Seung Kim, M.D., PhD Stanford University Medical Center, Stanford, CA, USA The Portnoy Family Research Grant Award Preservation of Islet Mass by Enhancing Islet Revascularization Hengjiang Dong, Ph.D. Mount Sinai School of Medicine, New York, NY, USA The Proctor & Gamble Company Career Development Award Regulatory T cells, immune privilege and islet allograft tolerance Zhenhua Dai, M.D., Ph.D. University of Texas Health Center, Tyler, TX, USA Rancho Santa Fe Women’s Fund Drug Development for Beta Cell Regeneration Fred Levine, M.D. University of California San Diego, San Diego, CA, USA The Sagan Family Program Project Basilximab and oral FTY720 and RAD 001 in islet transplantation Bernard Hering, M.D. University of Minnesota, Minneapolis, MN, USA Laura and Todd Templeton JDRF Academic Research and Development Award: A High Throughput Exploration Platform for Beta Cell Replenishment Douglas Melton, PhD, Harvard Stem Cell Institute, Cambridge, MA, USA The Louis Vance Family In Honor of Kathryn Vance Research Grant Beta Cell Consortium, recognizing the work of Anthony Atala, M.D. The Wake Forest Institute for Regenerative Medicine, Winston Salem, NC, USA The Louis Vance Family In Honor of Kathryn Vance Research Grant Targeted Expression of Insulin to Intestinal Endocrine Cells Timothy Kieffer, Ph.D. University of British Columbia, Vancouver, British Colombia, Canada METABOLIC CONTROL In Honor of Lillian Branka Continuous Glucose Monitoring in Youth Lori Laffel, M.D., M.P.H. Joslin Diabetes Center, Boston, MA, USA REPL ACEMENT Triad Foundation Penny and Bob Barnhill Beta Cell Consortium, Production of functioning Beta cells from human amniotic fluid stem cells Anthony Atala, M.D. The Wake Forest Institute for Regenerative Medicine, Winston Salem, NC, USA 40 Named Grants Program The Wattles Family Foundation in Honor of Conner Wattles Cell Fate Potential of Putative Progenitor Cells from Telomerase Tg Mice David Breault, M.D., Ph.D. Children’s Hospital, Boston, MA, USA Joe and Linda White Beta Cell Consortium, recognizing the work of Anthony Atala, M.D. The Wake Forest Institute for Regenerative Medicine, Winston Salem, NC, USA The Flora and Stuart Mason Postdoctoral Fellowship Award Identification of progenitor cells of beta-cells in adult human pancreas Shigeru Yatoh, M.D., Ph.D. Joslin Diabetes Center, Boston, MA, USA Giles W. and Elise G. Mead Foundation Career Development Award Derivation of Glucose Responsive Insulin Producing (GRIP) Cells from Human Pluripotent Stem Cells Michael Shamblott, Ph.D. Johns Hopkins University School of Medicine, Baltimore, MD, USA In Honor of Steven G. Mihaylo Career Development Award Promoting endodermal and pancreatic differentiation of ES cells James Wells, Ph.D. Children’s Hospital Medical Center, Cincinnati, OH, USA In Memory of Stephen Robinson Postdoctoral Fellowship Award Estrogen and androgen receptor signaling and pancreatic beta-cell survival Cedric Le May, Ph.D. Baylor College of Medicine, Houston, TX, USA The Schubert Family Postdoctoral Fellowship Award Characterization of cMaf in Development of Pancreatic Endocrine Cells Wataru Nishimura, M.D., Ph.D. Joslin Diabetes Center, Boston, MA, USA In Honor of Michael and Diane Stephens Studies on the Role of Sox Genes in islet Cell Differentiation and function Maike Sander, M.D. University of California, Irvine, CA, USA In Honor of Arthur Zaltzman and Kimberly Kessler Mindel Research Grant Generation of insulin-producing cells from human bone marrow cells Shimon Efrat, Ph.D. Tel Aviv University, Tel Aviv, Israel REGENERATION The Abrams Family Research Grant, In Honor of Ashley Abrams Role of Netrins and their receptors in the developing pancreas Vincenzo Cirulli, M.D., Ph.D. University of California, San Diego, La Jolla, CA, USA Angela and Gregg Bartlett in honor of Alexa and Carys Bartlett Postdoctoral Fellowship Award A Dynamic approach to investigate beta-cell formation and function Sapna Puri, Ph.D. The Regents of the University of California, CA, USA Discover Financial Services, A Morgan Stanley Company Career Development Award Mechanisms of Augmentation of Insulin Secretion in Rat and Human Pancreatic Islets Susanne G. Straub, Ph.D. Cornell University, Ithaca, NY, USA Kogan Family Foundation Academic R&D Award Genetically Modified huES Cells: Differentiation to insulin-producing cells Joseph Itskovitz-Eldor, M.D. Technion-Israel Institute of Technology, Haifa, Israel The Lewis-Sebring Family Foundation Research Grant Insulin-producing cells derived from stem cells: Evaluation before and after transplantation Gordon Weir, M.D. Joslin Diabetes Center, Boston, MA, USA 41 Financial Report 42 Financial Information 7% 7% 18% 68% FUNCTIONAL EXPENSES $216.6M for the year 2007 n M a n a ge me n t & Ge n e ra l $ 15. 4 M n Fu n d ra i si n g $ 14 . 7M R es ea rch & Ed uca t i on Prog ra m $ 186.5M n Pu b li c E d u ca ti o n $ 3 9 . 9 M n Re se a rch Ad mi n i stra ti o n $ 14 6 . 6M 86% 21% 5% 11% 63% PUBLIC SUPPORT AND REVENUE $228.7M for the year 2007 n Co n tr i b u ti o n s $ 4 9 . 0 M n In te r n a ti o n a l Affi li a te Tra n sfe rs $12 .2 M n Reve n u e $ 25. 0 M n S p e ci a l E ve n ts (In clu d i n g Wa lk) $142 .3M R EPORT OF IND E P E N DE N T A U DI TO R S To the Board of Directors The Juvenile Diabetes Research Foundation International In our opinion, the accompanying statements of financial position and the related statements of activities, cash flows and functional expenses present fairly, in all material respects, the financial position of The Juvenile Diabetes Research Foundation International and its Chapters (the “Foundation”) at June 30, 2007 and 2006, and the changes in their net assets and cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. These financial statements are the responsibility of the Foundation’s management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits of these statements in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. New York, New York September 21, 2007 43 Statements of Financial Position (in thousands) 2007 $ 49,904 160,107 4,615 21,597 370 3,586 2,041 1,690 $ 243,910 $ $ 2006 21,448 144,932 4,723 23,930 181 2,407 2,024 1,727 201,372 ASSETS Cash and cash equivalents Investments Receivables Accrued income Contributions receivable, net Sundry receivables Assets related to Charitable Remainder Trusts Fixed assets, net Prepaid expenses and other assets Total assets LIABILITIES AND NET ASSETS Liabilities Accounts payable and accrued liabilities Liabilities related to Charitable Remainder Trusts Accrued rent escalation Deferred credit Deferred revenue Research grants payable Total liabilities Commitments and contingencies Net assets Unrestricted Temporarily restricted Permanently restricted Total net assets Total liabilities and net assets $ 23,169 26,099 5,040 54,308 243,910 $ 10,473 26,659 5,042 42,174 201,372 $ 11,461 1,809 410 181 4,647 171,094 189,602 $ 10,699 1,316 541 240 4,033 142,369 159,198 See accompanying notes to financial statements. The Juvenile Diabetes Research Foundation International and Its Chapters Years Ended June 30, 2007 and 2006 44 Statements of Activities (in thousands) Unrestricted Temporarily Permanently Restricted Restricted 2007 Total Unrestricted Temporarily Permanently Restricted Restricted 2006 Total PUBLIC SUPPORT AND REVENUE Public support Contributions Special event Proceeds Direct expenses Contributions from affiliates Total public support Revenue Investment income Advertising income Other Total revenue Total public support and revenue 24,314 254 504 25,072 229,284 2 2 (11,388) (560) (2) (2) (2) 24,314 254 504 25,072 228,722 14,825 287 531 15,643 10,417 195,603 (10,417) 1,204 (80) (80) (80) 14,745 287 531 15,563 196,727 169,325 (26,985) 12,217 192,824 10,826 169,325 (26,985) 12,217 203,650 153,651 (25,396) 7,975 169,543 11,621 153,651 (25,396) 7,975 181,164 $ 38,267 $ 10,826 $$ 49,093 $ 33,313 $ 11,621 $$ 44,934 Net assets released from restrictions 11,388 EXPENSES Program services Research support Public education Supporting services Management and general Fund raising Total expenses Change in net assets 15,447 14,651 30,098 216,588 12,696 (560) (2) 15,447 14,651 30,098 216,588 12,134 13,582 14,631 28,213 196,191 (588) 1,204 (80) 13,582 14,631 28,213 196,191 536 146,614 39,876 186,490 146,614 39,876 186,490 131,227 36,751 167,978 131,227 36,751 167,978 NET ASSETS Beginning of year End of year 10,473 $ 23,169 26,659 $ 26, 099 5,042 $ 5,040 42,174 $ 54,308 11,061 $ 10,473 25,455 $ 26,659 5,122 $ 5,042 41,638 $ 42,174 See accompanying notes to financial statements. The Juvenile Diabetes Research Foundation International and Its Chapters Years Ended June 30, 2007 and 2006 45 Statements of Cash Flows (in thousands) 2007 $ 12,134 $ 2006 536 CASH FLOWS FROM OPERATING ACTIVITIES Change in net assets Adjustments to reconcile change in net assets to net cash used in operating activities Net realized gain from sale of investments Net unrealized appreciation on investments Depreciation and amortization Increase in receivables, net (Increase) decrease in prepaid expenses and other assets (Increase) decrease in split-interest agreements, net Increase (decrease) in accounts payable and accrued liabilities Increase (decrease) in accrued rent escalation Increase (decrease) in deferred credit Increase in deferred revenue Increase in research grants payable Net cash provided by operating activities (6,597) (14,289) 839 2,252 37 (686) 762 (131) (59) 614 28,725 23,601 (7,592) (3,419) 646 (1,188) 140 (34) (441) (168) (59) 325 19,215 7,961 CASH FLOWS FROM INVESTING ACTIVITIES Purchase of fixed assets Purchase of investments Proceeds from sale of investments Net cash used in investing activities Net increase (decrease) in cash and cash equivalents (856) (5,789) 11,500 4,855 28,456 (1,123) (49,084) 30,701 (19,506) (11,545) CASH AND CASH EqUIVALENTS Beginning of year End of year $ 21,448 49,904 $ 32,993 21,448 NON-CASH ACTIVITIES Investment securities contributed during the year $ 4,744 6,253 See accompanying notes to financial statements. The Juvenile Diabetes Research Foundation International and Its Chapters Years Ended June 30, 2007 and 2006 46 Statements of Functional Expenses (in thousands) PROGRAM SERVICES Research Support Research grants Payroll and related expenses Printing and promotional expenses $ 137,826 5,463 309 Public Education $22,814 3,418 5,595 3,418 2,641 1,990 $ 39,876 18.41% Total $ 137,826 28,277 3,727 6,818 4,740 2,983 2,119 $ 186,490 86.10% Management and General $9,719 814 2,513 668 834 899 $ 15,447 7.13% SUPPORTING SERVICES Fund Raising $8,728 1,995 2,053 883 578 414 $ 14,651 6.77% Total $18,447 2,809 4,566 1,551 1,412 1,313 $ 30,098 13.90% 2007 Total Expenses $ 137,826 46,724 6,536 11,384 6,291 4,395 3,432 $ 216,588 100.00% Office rent and related expenses, including depreciation and amortization 1,223 Meetings and conferences Professional services Miscellaneous Percentage of total 1,322 342 129 $ 146,614 67.69% (in thousands) PROGRAM SERVICES Research Support Research grants Payroll and related expenses Printing and promotional expenses Office rent and related expenses, including depreciation and amortization Meetings and conferences Professional services Miscellaneous Percentage of total $ 122,313 5,204 287 1,113 1,380 731 199 $ 131,227 66.89% Public Education $21,549 3,325 5,379 2,721 1,420 2,357 $ 36,751 18.73% Total $ 122,313 26,753 3,612 6,492 4,101 2,151 2,556 $ 167,978 85.62% Management and General $8,566 751 2,264 601 368 1,032 $ 13,582 6.92% SUPPORTING SERVICES Fund Raising $8,537 1,923 2,025 994 333 819 $ 14,631 7.46% Total $17,103 2,674 4,289 1,595 701 1,851 $ 28,213 14.38% 2006 Total Expenses $ 122,313 43,856 6,286 10,781 5,696 2,852 4,407 $ 196,191 100.00% See accompanying notes to financial statements. The Juvenile Diabetes Research Foundation International and Its Chapters Years Ended June 30, 2007 and 2006 47 Notes to Financial Statements 1 . O R GAN IzAT I ON The mission of the Juvenile Diabetes Research Foundation International and its Chapters (the “Foundation”) is to find a cure for diabetes and its complications through the support of research. The Foundation solicits contributions from the public and engages in various fund raising activities. Funds raised are used to support Type 1 diabetes research. In addition, the Foundation engages in advocacy efforts aimed at increasing federal funding of Type 1 diabetes research. The financial statements of the Foundation include the accounts of The Juvenile Diabetes Research Foundation International and its Chapters located throughout the United States, which grant restricted and unrestricted funds to the Foundation in support of its programs. The Foundation has international affiliates located in Canada, Australia, United Kingdom and a number of other countries. The financial statements of those organizations are not included in the foregoing financial statements of the Foundation since the Foundation does not exercise control over the management and operations of the international affiliates. The Foundation is a not-for-profit organization exempt from Federal income taxes under Section 501(c)(3) of the Internal Revenue Code. receipt, if donated. Valuations of securities are based on published closing prices on the last day of the fiscal year. Fair value of certain alternative investments amounting to approximately $41 million and $38 million at June 30, 2007 and 2006, respectively, is estimated by respective external investment managers where market values are not readily ascertainable. These valuations involved assumptions and estimation methods. The Foundation believes that the carrying amount of its alternative investments is a reasonable estimate of fair value as of June 30, 2007 and 2006. Because alternative investments do not have readily determinable market values, the estimated value is subject to uncertainty and, therefore, may differ from the value that would have been used had a ready market for the investment existed and such differences could be material. FIXED ASSETS Fixed assets, which consist of furniture, equipment and leasehold improvements, are recorded at cost. Depreciation is provided on a straight-line basis over the estimated useful lives of the assets, which approximate three to ten years for furniture and equipment. Leasehold improvements are amortized on a straight-line basis over the shorter of the life of the asset or the lease term. FAIR VALUE OF FINANCIAL INSTRUMENTS 2 . SUMM A R y OF S IG N I F I CANT ACCO U NT I NG P O LI CI ES NET ASSET CLASSIFICATIONS The Foundation reports information regarding its financial position and activities according to three classes of net assets: unrestricted, temporarily restricted and permanently restricted. Unrestricted net assets are not restricted by donors, or the donor-imposed restrictions have expired. Temporarily restricted net assets contain donor-imposed restrictions that permit the Foundation to use or expend the assets as specified. The restrictions are satisfied either by the passage of time or by action of the Foundation. Permanently restricted net assets contain donor-imposed restrictions that stipulate the resources be maintained permanently, but permit the Foundation to use or expend part or all of the income derived from the donated assets for either specified or unspecified purposes. When a time restriction ends or a purpose restriction is accomplished, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the statement of activities as net assets released from restrictions. However, donor restricted contributions whose restrictions are met in the year of contribution are reported as unrestricted support. CONTRIBUTIONS Financial instruments are defined to include: cash and cash equivalents, investments, receivables, assets related to split-interest agreements, accounts payable and liabilities related to split-interest agreements. The fair value of investments is discussed in Note 3. The carrying amount of the Foundation’s remaining financial instruments approximates fair value. ALLOCATION OF JOINT COSTS The Foundation allocates joint costs between fund raising and program services or management and general in accordance with the American Institute of Certified Public Accountants Statement of Position (SOP) 98-2, “Accounting for Costs of Activities of Not-for-Profit Organizations and State and Local Governmental Entities That Include Fund Raising”. USE OF ESTIMATES The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Certain prior year amounts have been reclassified to conform with the current year presentation. Contributions and promises to contribute are recognized as income when received or when they become unconditional promises to contribute, at fair value. The Foundation records contributions as temporarily restricted if they are received with donor stipulations that limit their use, either through purpose or time restrictions, and those stipulations have not expired. When donor restrictions expire in subsequent years, that is, when a purpose restriction is fulfilled or a time restriction ends, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the statement of activities as net assets released from restrictions. Contributions received with donor stipulations that limit their use which expire in the same reporting period are recorded as unrestricted contributions. Contributions received for subsequent fiscal years’ events, primarily walk events, are deemed conditional and are therefore recorded as deferred revenue and are recognized as revenue in the fiscal year the event takes place, which is generally within one year. As of June 30, 2007 and 2006, the Foundation recorded $4,647 and $4,033 as deferred revenues, respectively. The Foundation administers two types of split interest agreements—Charitable Gift Annuities and Charitable Remainder Trusts. With Charitable Gift Annuities, the Foundation receives cash or marketable securities from a donor in exchange for an annuity to be distributed for a fixed amount over the lifetime or lifetimes of the donor or other beneficiaries, not to exceed two persons. Upon the death of the annuitant or survivor of the annuitants, the Foundation is entitled to full use of the remainder. With Charitable Remainder Trusts administered by the Foundation, the Foundation receives donated assets as Trustee under a trust agreement established by the donor in exchange for an income stream to be distributed to the donor and/or other beneficiaries over a specified period of time. The distribution to the donor or other beneficiaries may be a fixed dollar amount (an annuity trust) or percentage of the fair market value of the trust as determined annually (unitrust). Upon the termination of the trust, the Foundation is entitled to full use of the remainder. For both Charitable Gift Annuities and Charitable Remainder Trusts, a related liability is recorded for the actuarially determined present value of the obligation to the annuitant or annuitants. The discount rates used to calculate the liability range between 3.6% and 8.2% at June 30, 2007. For Charitable Gift Annuities, the assets received are held as general assets of the Foundation, and the annuity liability is a general obligation of the Foundation. The Foundation has volunteers who have donated significant amounts of their time to the Foundation’s program services and to its fund-raising campaigns. Such contributed services do not meet the criteria for recognition as the value of such services cannot be readily measured and, accordingly, are not reflected in the accompanying financial statements. CASH AND CASH EqUIVALENTS 3. IN v ESTM EN TS Investments at June 30, 2007 and 2006 consisted of the following: 2007 Cost Fixed income securities Equity securities including mutual funds and hedge funds Total investments $ 33,301 80,642 $ 113,943 Fair Value $ 32,421 127,686 $ 160,107 Cost $ 33,680 79,378 $ 113,058 2006 Fair Value $ 32,584 112,348 $ 144,932 Included in investments are amounts related to Charitable Gift Annuities totaling $2,407 and $1,987 at June 30, 2007 and 2006, respectively. The Foundation’s investments are exposed to various risks, such as market and credit risks. Because of the risk associated with such investments, it is possible that changes in their values will occur and that such changes could materially affect the Foundation’s financial statements. The Foundation is exposed to credit risk in the event of nonperformance by the issuers of the fixed income securities. However, the Foundation does not anticipate such nonperformance. The components of investment income and its classification in the Statements of Activities for the years ended June 30, 2007 and 2006 were as follows: 2007 Temporarily Permanently Unrestricted Restricted Restricted Interest and dividends Unrealized gains Realized gains (losses) $ 3,401 14,287 6,626 $ 24,314 $3 (1) $2 $ 24 2 (28) $ (2) Total $ 3,428 14,289 6,597 $ 24,314 2006 Temporarily Permanently Unrestricted Restricted Restricted Interest and dividends Unrealized gains Realized gains (losses) $ 3,705 3,518 7,602 $ 14,825 $3 (3) $$ 26 (99) (7) $ (80) Total $ 3,734 3,419 7,592 $ 14,745 Cash and cash equivalents include cash balances of the Foundation and money market accounts. At times, cash and money market balances may be in excess of the Federal Deposit Insurance Corporation limits. The Foundation has not experienced any losses in such accounts. INVESTMENTS Investments, including assets related to split-interest agreements, are carried at fair value. Realized and unrealized gains and losses are recorded on the statement of activities and determined by comparison of cost, computed on a first-in, first-out basis, with proceeds or fair value. Cost of securities is determined by purchase price, if purchased, or fair value at date of Investment expenses relating to investment advisors, managers and custodians and other bank charges are recorded as reductions to interest and dividend income. 48 Notes to Financial Statements 4. RE TI R E M E N T PL A N The Foundation has a defined contribution pension plan which covers substantially all employees. The Foundation’s expense for the years ended June 30, 2007 and 2006 was $1,529 and $1,782, respectively. The gross amount of the payables are due as follows Less than one year One to two years $ 163,496 7,598 $ 171,094 $ 132,440 9,929 $ 142,369 5 . ACCO U N T S PAyA BL E AND ACCRU ED LI AB I LI T I ES Accounts payable and accrued liabilities at June 30, 2007 and 2006 consisted of: 2007 Accounts payable and accrued expenses Accrued vacation Liability related to charitable gift annuities Total accounts payable and accrued liabilities $ 8,115 2,045 1,301 $ 11,461 2006 $ 7,596 1,723 1,380 $ 10,699 Research grants have been discounted to their present value as of June 30, 2007 and 2006 using discount rates of 4.91% and 5.21%, respectively. 10. COM M ITM EN TS AN D CON TIN GEN C IES RESEARCH GRANTS As of June 30, 2007, there were conditional research grant commitments of $152,390 payable over the next five years. Such additional conditional commitments will be recognized in the Foundation’s financial statements when the conditions have been substantially met and are currently estimated to be due as follows: 2008 2009 2010 2011 and thereafter $ 82,230 46,726 15,289 8,145 $ 152,390 LEASES 6 . CO NT R I BU T ION S R E C E I vAB LE Contributions receivable at June 30, 2007 and 2006 consisted of: 2007 Gross contributions receivable, due Less than one year Two to five years Thereafter Less Unamortized discount to present value Allowance for doubtful accounts (1,467) (1,597) $ 21,597 (1,876) (2,211) $ 23,930 $ 9,040 15,119 502 24,661 $ 9,813 15,994 2,210 28,017 2006 Contributions receivable have been discounted to their present value at the date the original unconditional promise to give was made. As of June 30, 2007 and 2006 such contributions receivable were discounted using average rates of 4.98% and 5.13%, respectively. Contributions deemed uncollectible are recorded as bad debt expense. During the year ended June 30, 2007 and 2006, the Foundation provided for $1,920 and $2,120 of contributions receivable, respectively, deemed to be uncollectible. Effective January 1, 1995, the Foundation entered into a 15-year lease agreement for executive office space in New York City. The lease provided for rental concessions at the beginning of the lease term and for rental increases over the minimum rent for the Foundation’s pro-rata share of increases in building operating expenses. As of June 2001, the Foundation leased additional office space for the executive office in the same building which also provided for rental increases over the minimum rent for the Foundation’s pro-rata share of increases in building operating expenses. Rent expense for the executive office was $1,136 and $1,048 for the years ended June 30, 2007 and 2006, respectively. As of June 30, 2007, a liability of $181 remains for the excess of the straight-line rent over the actual lease payments. The Foundation was also reimbursed for certain construction costs associated with leasehold improvements. The leasehold improvements and a corresponding deferred credit were recorded in 1995, both of which are being amortized on a straight-line basis over the term of the lease. The Foundation is also obligated under various leases for space occupied by certain U.S. Chapters. Rent expense including maintenance costs for the U.S. Chapters was $3,595 and $3,444 for the years ended June 30, 2007 and 2006, respectively. Rental commitments for all leases are as follows: 2008 2009 2010 2011 2012 and thereafter 4,416 3,742 2,376 1,361 1,864 $ 13,756 7 . F I x E D A SS ET S Fixed assets at June 30, 2007 and 2006 consisted of: 2007 Furniture and equipment Leasehold improvements Fixed assets, gross Less accumulated depreciation and amortization Fixed assets, net $ 3,948 2,038 5,986 (3,945) $ 2,041 2006 $ 3,216 1,914 5,130 (3,106) $ 2,024 Depreciation and amortization expense for the years ended June 30, 2007 and 2006 amounted to $839 and $646, respectively. 11. R ESTR ICTED N ET ASSETS TEMPORARILY RESTRICTED NET ASSETS 8. RE LAT ED- PA R T y T R A N S ACT I O NS During the years ended June 30, 2007 and 2006, the Foundation received the following contributions, included in the statement of activities, from affiliates. These contributions support the Foundation’s programs. 2007 JDRF - Canada JDRF - Australia JDRF - United Kingdom JDRF - Greece JDRF - Others $ 4,799 6,237 1,086 60 35 $12,217 2006 $ 5,341 1,997 592 45 $ 7,975 At June 30, 2007 and 2006, temporarily restricted net assets were available for the following purposes: 2007 Net contributions receivable and split interest agreements In support of DCC program (know your A1C) In support of various designated grants Research scientist award $ 23,362 2,230 465 42 $ 26,099 PERMANENTLY RESTRICTED NET ASSETS 2006 $ 24,996 1,621 42 $ 26,659 Totals for JDRF Australia in 2007 include $3.9 million funded by the Australian Government as part of the JDRF Islet Transplantation Program (“ITP”) in Australia. The program, which began in 2007, funds JDRF-approved grants at Australian medical and research institutions to address the basic science surrounding pre-clinical approaches to improve current state-ofthe-art islet transplantation techniques. Permanently restricted net assets are restricted to investment in perpetuity. At June 30, 2007 and 2006, the investment income derived from the following components of the permanently restricted net asset balance, exclusive of a minor portion of investment income reinvested in perpetuity in accordance with donor wishes, was expendable to support: 2007 Nondesignated program activities Research grants funding JDRF Artificial Pancreas Project Research grants at Virginia Mason Research Center $ 1,576 2,000 1,464 $ 5,040 2006 $ 1,576 2,000 1,466 $ 5,042 9 . RE SE A R C h G R A N T S PAyAB LE Research grants payable at June 30, 2007 and 2006 consisted of: 2007 Gross research grants payable Less Unamortized discount to present value (374) $ 171,094 (634) $ 142,369 $ 171,468 2006 $ 143,003 49 JDRF Chapters & Affiliates AL A BAMA Alabama Chapter, Birmingham ARI Z ONA Desert Southwest Chapter, Phoenix Southern Arizona Branch, Tucson ARKAN S A S Greater Arkansas Chapter, Little Rock Northwest Arkansas Branch, Fayetteville CA L I FOR NIA Inland Empire Chapter, Colton Los Angeles Chapter, Los Angeles Ventura Branch, Agoura Orange County Chapter, Irvine Northern CA Inland Chapter, Sacramento San Diego Chapter, San Diego Greater Bay Area Chapter, San Francisco Bakersfield Branch, Bakersfield COLORA D O Rocky Mountain Chapter, Greenwood Village Cheyenne Branch, Greenwood Village Colorado Springs Branch, Colorado Springs CON N E CT IC U T North Central CT/Western MA Chapter, Farmington Greater New Haven Chapter, Hamden Fairfield County Chapter, Norwalk D E L AWA R E Delaware Branch, Wilmington D I ST RI CT O F CO LU MB IA Capitol Chapter, Washington, DC FLORI DA South Florida Chapter, Ft. Lauderdale Southwest Florida Chapter, Sarasota Central Florida Chapter, Altamonte Springs North Florida Chapter, Jacksonville Greater Palm Beach County Chapter, West Palm Beach Tampa Bay Chapter, St. Petersburg GE ORGI A Georgia Chapter, Atlanta Low Country Branch, Atlanta HAWA I I Hawaii Chapter, Honolulu I L L I N OI S Illinois Chapter, Chicago I NDI ANA Indiana State Chapter, Indianapolis Northern Indiana Branch, South Bend I OWA Greater Iowa Chapter, Johnston Eastern Iowa Branch, Cedar Rapids KE NTU CKY Kentuckiana Chapter, Louisville LOU I SI ANA Louisiana Chapter, Baton Rouge Baton Rouge Branch, Baton Rouge North Louisiana Branch, Baton Rouge M AI NE New England / Maine Council, Portland M ARY LAND Maryland Chapter, Linthicum M ASSACH U SE T T S New England / Bay State Branch, Wellesley M I CH I GAN Metro-Detroit / Southeast MI Chapter, Southfield West Michigan Chapter, Grand Rapids M I NNE SOTA Minnesota Chapter, Bloomington M I SSI SSI P P I Mississippi Chapter, Jackson M I SSOU RI Kansas City Chapter, Kansas City Metro St. Louis / Greater MO Chapter, St. Louis NE B RASKA Lincoln Chapter, Lincoln Omaha Council Bluffs Chapter, Omaha NE VADA Nevada Chapter, Las Vegas Northern Nevada Branch, Reno NE W H AM P SH I RE New England / New Hampshire Branch, Manchester NE W JE RSEY Central Jersey Chapter, Shrewsbury South Jersey Branch, Cherry Hill Mid Jersey Chapter, East Brunswick Northern NJ / Rockland County Chapter, Englewood Cliffs NE W M E XI CO New Mexico Branch, Albuquerque N EW YO R K Western New York Chapter, Amherst Rochester Chapter, Rochester Northeastern NY / Hudson Valley Branch, Wappingers Falls Long Island Chapter, Melville New York City Chapter, New York New York City / Queens & Brooklyn Branch, New York New York City / Staten Island Branch, New York Westchester County Chapter, White Plains Northeastern NY / Capital Region Branch, East Greenbush Northeastern NY / Greater Adirondack Region Branch, Glens Falls Central New York Chapter, Liverpool N O R TH CAR O L IN A Piedmont Triad Chapter, Winston-Salem Charlotte Chapter, Charlotte Triangle / Eastern NC Chapter, Raleigh O HIO Greater Cincinnati Chapter, Cincinnati Northeast Ohio Chapter, Independence Greater Dayton Chapter, Dayton Mid-Ohio Chapter, Columbus Akron/Canton Branch, Independence Northwest Ohio Chapter, Toledo O K L AHO MA Central Oklahoma Chapter, Oklahoma City Tulsa Green Country Chapter, Tulsa O R EGO N Oregon / Southwest WA Chapter, Tigard PEN N SYLVAN IA Central PA Chapter, Harrisburg East Central PA Branch, Bala Cynwyd Western PA Chapter, Pittsburgh Northwestern PA Chapter, Erie Eastern PA Chapter, Bala Cynwyd R HO DE ISL AN D New England / Rhode Island Branch, Warwick SO UTH CAR O L IN A Palmetto Chapter, Columbia Western Carolinas Chapter, Greenville TEN N ESSEE East Tennessee Branch, Knoxville West Tennessee Branch, Collierville Middle Tennessee Branch, Brentwood TEXAS Greater Dallas Chapter, Dallas Greater Ft. Worth Arlington Chapter, Ft. Worth Houston Gulf Coast Chapter, Houston Panhandle Branch, Amarillo South Central Texas Chapter, San Antonio Austin Chapter, Austin El Paso Council, El Paso UTAH Utah Chapter, Salt Lake City VIR GIN IA Greater Blue Ridge Chapter, Roanoke Central Virginia Chapter, Richmond Tidewater Chapter, Norfolk WASHIN GTO N JDRF Northwest Chapter, Seattle Inland Northwest Branch, Spokane Western Montana Council, Seattle Seattle Guild, Seattle WEST VIR GIN IA West Virginia Branch, Roanoke WISCO N SIN Northeast Wisconsin Chapter, Menasha Western Wisconsin Chapter, Madison Southeastern WI Chapter, Wauwatosa J DR F A F F IL IAT E S JDR F AUSTR AL IA St. Leonards, NSW JDR F CAN ADA Markham, Ontario JDR F DEN MAR K Copenhagen JDR F HEL L AS Marousi, Greece JDR F IN DIA Salt Lake, Calcutta JDR F ISR AEL Tel Aviv JDR F ITALY Rome JDR F UN ITED K ING DOM London JDRF does not currently have offices in Alaska, Idaho, Kansas, Montana, North Dakota, South Dakota, Vermont, and Wyoming, but we are active in your region. For information about JDRF events in your area, please call 1-888-533-WALK, or email info@jdrf.org. 50 Board Members & Senior Staff BOARD OF DIRECTO R S Fernando Aguirre Don Aron Neil Beckerman Richard K. Bonness John Brady Jeffrey Brewer Mitchell H. Caplan Dayton Coles Cynthia Ford Richard M. Fuscone Joseph Gardner, Ph.D. Chip Halverson Robert R. Hindle Judy M. Hunt Francis J. Ingrassia David W. Johnson Robert Wood Johnson IV Robert N. Klein II Richard Kirkland Richard P. Levy James F. McDonald Patrick McFeeley Leo F. Mullin George R. Nethercutt, Jr. Nettleton S. Payne II, M.D. Gail Pressberg Lewis R. Runnion Pam Sagan Glen E. Tullman James C. Tyree, Chairman Michael White Peter Wilson William T. Young, Jr. Rodney W. Zemmel BOARD O F C HA N C E LLO RS Don Aron, Chairman Robert Auerbach Gordon D. Barker Joan Beaubaire Crandall Bowles Erskine Bowles Max C. Chapman, Jr. Sanford Cloud, Jr. Judi Cochran Ross A. Cooley Don Corrao Lawrence DeGeorge Lee Ducat Samuel D. Ewing, Jr. Gerald Fishbone, M.D. William Fuller Eileen Gelick Robert D. German, Esq. David Glusman Marilyn Gomm William Graves Roslyn Greenspon Eric Harkna Krayna Hecht Margaret Conn Himelfarb, M.P.H. Michael J. Hopkins, Esq. Terry A. Jackson Fran Jacoby Larry King Joann Leatherby, Esq. Jan Leeper Stephen Leeper, DDS S. Robert Levine, M.D. Erwin Lurie Carol Lurie Steven M. Merdinger Harry Moseley Penny Moseley J. Richard Munro Willard J. Overlock, Jr. Penn Payne, Esq. Sandra Puczynski, Ph.D. Charles J. queenan III S E N I O R S TA FF President & Chief Executive Officer Arnold W. Donald Executive Vice President, Development & Chief Operating Officer Robin Harding Vice President, Strategic Communications & Information Technology William Ahearn Chief Human Resources Officer Gerri Bostick Senior Vice President, Research Paul Burn, Ph.D. Vice President, Major Donor Relations Amy Franze Chief Scientific Officer Robert A. Goldstein, M.D., Ph.D. Executive Vice President, Research Richard A. Insel, M.D. Chief Information Officer Charles LaPlaca Chief Financial Officer Edward Sebald Senior Vice President, Development & Field Operations Benita Shobe Vice President, Government Relations Lawrence Soler Vice President and Chief Medical Officer Paul Strumph, M.D. Anthony Reeves Kenneth M. Rich Jim Robbins Mark Rubenstein Bob Samuels Alyce Satsky Helaine Shiff Sandra D. Silvestri Adam Singer Harold Smethills Emily Spitzer James Stuart Jr. Anne Zaring Photography: Camera One (Cover & Page 1); Ed Eckstein (Pages 14-25); Peter Maclaurin (Page 26); Family of Beverly Berry (Page 27) Design: Cobalt Design Group 3 JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL 120 Wall Street New York, NY 10005-4001 800-533-CURE 212-785-9500 www.jdrf.org